Search

Your search keyword '"Gastroenterology Unit"' showing total 8,910 results
Start Over Author "Gastroenterology Unit"
8,910 results on '"Gastroenterology Unit"'

2. Exogenous and Endogenous Risk Factors for Early-onset Colorectal Cancer (DEMETRA)

Author

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, Ospedale Civile Guglielmo da Saliceto, Piacenza, Italy, Centro di Riferimento Oncologico di Aviano, Aviano, Italy, Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari, Bari, Italy, Gastroenterology Unit, University Hospital of Padova, Padova, Italy, Clinical Gastroenterology Unit, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy, IRCCS Arcispedale S. Maria Nuova - Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy, Azienda Ospedaliera San Gerardo di Monza, Monza, Italy, Azienda ULSS5 Polesana, Rovigo, Italy, Istituto Tumori Regina Elena - IRCCS IFO, Roma, Italy, University Hospital of Padova, Padova, Italy, IRCCS De Bellis, Castellana Grotte, Italy, University Hospital HELIOS Klinikum Wuppertal, Center for Hereditary Tumors, University of Witten-Herdecke, Wuppertal, Germany, Hospital of the University of Munich (LMU), Campus Großhadern, Munich, Germany, Hospital Clínic de Barcelona, University of Barcelona, Barcelona, Spain, Helsinki University Hospital, Helsinki, Finland, Oslo University Hospital (OUS), Institute for Cancer Genetics and Informatics Norwegian Radium Hospital, Oslo, Norway, Department of Medicine University of Chicago Medicine, Illinois, USA, University of Colorado Hospital, CO, USA, University of Michigan Ann Arbor, Michigan, USA, Columbia University Irving Medical Center, New York, NY, The James Comprehensive Cancer Center, Columbus, OH, USA, Ohio State University, Cleveland Clinic Main Campus, Cleveland, OH, USA, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia, and Cavestro Giulia Martina MD PhD, Prof Cavestro Giulia Martina

Published
2023

3. Thalidomide in Pediatric Inflammatory Bowel Diseases. (TALIBDP)

Author

Ospedale Meyer, Pediatric Gastroenterology Unit, IRCCS Gaslini, Genoa., Vittore Buzzi Children's Hospital, University of Pisa, University of Messina, Università degli Studi di Brescia, University of Trieste, and Alessandro Ventura, MD

Published
2012

7. Two-hour lactose breath hydrogen test

Author

Trevor A. Robb, Geoffrey P. Davidson, and Gastroenterology Unit

Subjects
Chromatography, business.industry, Gastroenterology, Breath hydrogen test, chemistry.chemical_compound, chemistry, Breath Tests, Pediatrics, Perinatology and Child Health, Medicine, Humans, Lactose, business, Child, Hydrogen
Published
1987

14. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn’s disease

Author

[Chaparro M] Gastroenterology Unit. Hospital Universitario de La Princesa, Madrid, Spain. Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain. Universidad Autónoma de Madrid, Madrid, Spain. [Aterido A, Marsal S, Julia A] Grup de Recerca en Reumatologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Guerra I] Gastroenterology Unit, Hospital Universitario de Fuenlabrada, Madrid, Spain. Instituto de Investigación de Hospital La Paz (IdiPaz), Madrid, Spain. [Iborra M] Gastroenterology Unit, Hospital Universitario de La Fe, Valencia, Spain. [Cabriada JL] Gastroenterology Unit, Hospital Universitario de Galdakano, Vizcaya, Spain. [Bujanda L] Gastroenterology Unit, Hospital Universitario de Donostia, San Sebastián, Spain. Instituto Biodonostia, San Sebastián, Spain. UPV/EHU, Bilbao, Spain. Ikerbasque, Bilbao, Spain and Hospital Universitari Vall d'Hebron

Subjects
Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Cytokine::Receptors, Tumor Necrosis Factor [CHEMICALS AND DRUGS], Genoma humà - Mapatge, ambiente y salud pública::salud pública::métodos epidemiológicos::diseño de la investigación epidemiológica::ambiente y salud pública::salud pública::métodos epidemiológicos::estudio de asociación genómica completa [ATENCIÓN DE SALUD], Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases::Crohn Disease [DISEASES], Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Research Design::Environment and Public Health::Public Health::Epidemiologic Methods::Genome-Wide Association Study [HEALTH CARE], Aminoácidos, Péptidos y Proteínas::Proteínas::Proteínas de la Membrana::Receptores de Superficie Celular::Receptores Inmunológicos::Receptores de Citocinas::Receptores del Factor de Necrosis Tumoral [COMPUESTOS QUÍMICOS Y DROGAS], Crohn, Malaltia de, Factor de necrosi tumoral, enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal::enfermedad de Crohn [ENFERMEDADES]
Published
2021

15. Gene signatures of early response to anti-TNF drugs in pediatric inflammatory bowel disease

Author

Ana Moreno-Álvarez, Lorena Magallares, Concepcion Álvarez del Vayo, Rosana Muñoz-Codoceo, María J. Fobelo, R. García-Romero, Sara Salvador-Martín, Irene Raposo-Gutiérrez, Gemma Pujol-Muncunill, Antonio Millán-Jiménez, Vicente Merino-Bohórquez, Alejandro Rodriguez-Martinez, Rafael González de Caldas, Inés Loverdos, José A. Blanca-García, Víctor Manuel Navas-López, Francisco J. Eizaguirre, Alfonso Solar-Boga, Luis A. López-Fernández, Mar Tolin, César Sánchez, María Sanjurjo-Sáez, Ferrán Bossacoma, Carmen Gallego-Fernández, Eva Martínez-Ojinaga, Oscar Segarra, UAM. Departamento de Pediatría, Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-IP), [Salvador-Martín,S, Raposo-Gutiérrez,I, Sanjurjo-Sáez,M, López-Fernández,LA] Pharmacy Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. [Navas-López,V] Pediatric Gastroenterology and Nutrition Unit, Hospital Regional Universitario de Málaga, IBIMA Multidisciplinary Group for Pediatric Research, Málaga, Spain. [Gallego-Fernández,C] Pharmacy Department, Hospital Regional Universitario de Málaga, Málaga, Spain. [Moreno-Álvarez,A, Solar-Boga,A] Pediatric Gastroenterology Unit, Department of Pediatrics, A Coruña University Hospital, A Coruña, Spain. [Muñoz-Codoceo,R] Department of Pediatric Gastroenterology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain. [Magallares,L, Martínez-Ojinaga,E] Department of Pediatric Gastroenterology, University Hospital La Paz, Madrid, Spain. [Fobelo,MJ] Pharmacy Service, Hospital Virgen de Valme, Sevilla, Spain. [Millán-Jiménez,A] Pediatric Gastroenterology Unit, Hospital Virgen de Valme, Sevilla, Spain. [Rodriguez-Martinez,A] Pediatric Gastroenterology, Hepatology and Nutrition Unit, Hospital Universitario Virgen del Rocio, Seville, Spain. [Vayo,CA] Pharmacy Service, Hospital Universitario Virgen del Rocio, Seville, Spain. [Sánchez,C, Tolin,M] Gastroenterology Unit, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain. [Bossacoma,F] Fundació Sant Joan de Déu, Fundació Salut Emporda, Barcelona, Spain. [Pujol-Muncunill, G] Department of Pediatric Gastroenterology, Hepatology and Nutrition, Hospital Sant Joan de Déu, Barcelona, Spain. [González de Caldas,R] Pediatric Gastroenterology Unit, Hospital Reina Sofía, Córdoba, Spain. [Loverdos,I] Pediatric Gastroenterology, Hepatology and Nutrition Unit, Hospital de Sabadell, Corporació Sanitària Universitària Parc Taulí, Barcelona, Spain. [Blanca-García,JA] Pediatric Gastroenterology Unit, Hospital Puerta del Mar, Cadiz, Spain. [Segarra,O] Pediatric Gastroenterology Unit, Hospital Universitario Vall d’Hebrón, Barcelona, Spain. [Eizaguirre,FJ] Pediatric Gastroenterology Unit, Hospital Universitario Donostia, San Sebastián, Spain. [García-Romero,R] Pediatric Gastroenterology Unit, Hospital Infantil Miguel Servet, Zaragoza, Spain. [Merino-Bohórquez,V] UGC Pharmacy Department, Hospital Virgen de la Macarena, Sevilla, Spain., and This work was funded by Instituto de Salud Carlos III (grants numbers PI16/00559 and PI19/00792), Consejería de Educación y Deporte de la Comunidad de Madrid (grant number PEJ16/MED/AI-1260), and by the Gregorio Marañón Health Research Institute (grant number PRE-2018-2), The study was cofunded by ERDF Funds (FEDER) from the European Commission, 'A way of making Europe'.

Subjects
Male, 0301 basic medicine, Crohn’s disease, Phenomena and Processes::Genetic Phenomena::Genetic Processes::Gene Expression Regulation [Medical Subject Headings], Anti-Inflammatory Agents, Inflammatory bowel disease, Gastroenterology, Diseases::Digestive System Diseases::Gastrointestinal Diseases::Intestinal Diseases::Inflammatory Bowel Diseases [Medical Subject Headings], Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Carrier Proteins::Adaptor Proteins, Signal Transducing::Smad Proteins::Smad Proteins, Inhibitory::Smad7 Protein [Medical Subject Headings], lcsh:Chemistry, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Chemicals and Drugs::Biological Factors::Intercellular Signaling Peptides and Proteins::Tumor Necrosis Factors::Tumor Necrosis Factor-alpha [Medical Subject Headings], 0302 clinical medicine, adalimumab, Child, lcsh:QH301-705.5, Spectroscopy, Persons::Persons::Age Groups::Infant [Medical Subject Headings], Crohn's disease, General Medicine, Ulcerative colitis, Computer Science Applications, Treatment Outcome, Antirheumatic Agents, Child, Preschool, biomarker, Biomarker (medicine), Population study, Female, 030211 gastroenterology & hepatology, medicine.drug, alpha-Defensins, medicine.medical_specialty, Adolescent, Medicina, Phenomena and Processes::Genetic Phenomena::Genetic Processes::Gene Expression::Transcription, Genetic::Transcriptome [Medical Subject Headings], Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides::Antimicrobial Cationic Peptides::Defensins::alpha-Defensins [Medical Subject Headings], Check Tags::Male [Medical Subject Headings], Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Inflammatory Agents [Medical Subject Headings], Article, Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antirheumatic Agents [Medical Subject Headings], Catalysis, Smad7 Protein, Persons::Persons::Age Groups::Adolescent [Medical Subject Headings], Inorganic Chemistry, 03 medical and health sciences, Colitis ulcerosa, Internal medicine, medicine, Adalimumab, Humans, Receptors, Tumor Necrosis Factor, Type II, Persons::Persons::Age Groups::Child [Medical Subject Headings], RNA, Messenger, Enfermedad de Crohn, Physical and Theoretical Chemistry, Molecular Biology, ulcerative colitis, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Prognosis::Treatment Outcome [Medical Subject Headings], Tumor Necrosis Factor-alpha, business.industry, Organic Chemistry, Infant, Biomarker, Chemicals and Drugs::Nucleic Acids, Nucleotides, and Nucleosides::Nucleic Acids::RNA::RNA, Messenger [Medical Subject Headings], Inflammatory Bowel Diseases, medicine.disease, Toll-Like Receptor 2, Triggering Receptor Expressed on Myeloid Cells-1, Infliximab, Chemicals and Drugs::Biological Factors::Antigens::Antigens, Surface::Antigens, Differentiation::Antigens, CD::Receptors, Tumor Necrosis Factor, Type II [Medical Subject Headings], Biomarcadores, 030104 developmental biology, Gene Expression Regulation, lcsh:Biology (General), lcsh:QD1-999, Check Tags::Female [Medical Subject Headings], Pharmacogenomics, gene expression, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Pattern Recognition::Toll-Like Receptors [Medical Subject Headings], Gene expression, Transcriptome, infliximab, business, Persons::Persons::Age Groups::Child::Child, Preschool [Medical Subject Headings], Expresión génica
Abstract

Around a 20&ndash, 30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs can induce and maintain remission in IBD, however, up to 30% of patients do not respond. The aim of the work was to identify markers that would predict an early response to anti-TNF drugs in pediatric patients with IBD. The study population included 43 patients aged &lt, 18 years with IBD who started treatment with infliximab or adalimumab. Patients were classified into primary responders (n = 27) and non-responders to anti-TNF therapy (n = 6). Response to treatment could not be analyzed in 10 patients. Response was defined as a decrease in over 15 points in the disease activity indexes from week 0 to week 10 of infliximab treatment or from week 0 to week 26 of adalimumab treatment. The expression profiles of nine genes in total RNA isolated from the whole-blood of pediatric IBD patients taken before biologic administration and after 2 weeks were analyzed using qPCR and the 2&minus, ∆∆Ct method. Before initiation and after 2 weeks of treatment the expression of SMAD7 was decreased in patients who were considered as non-responders (p value &lt, 0.05). Changes in expression were also observed for TLR2 at T0 and T2, although that did not reach the level of statistical significance. In addition, the expression of DEFA5 decreased 1.75-fold during the first 2 weeks of anti-TNF treatment in responders, whereas no changes were observed in non-responders. Expression of the SMAD7 gene is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD. TLR2 and DEFA5 need to be validated in larger studies.

Published
2020

19. Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's disease

Author

Chaparro, María, Aterido, Adrià, Guerra, Iván, Iborra, Marisa, Cabriada, José Luis, Bujanda, Luis, Taxonera, Carlos, García-Sánchez, Valle, Marín-Jiménez, Ignacio, Barreiro de-Acosta, Manuel, Vera, Isabel, Martín-Arranz, María Dolores, Hernández-Breijo, Borja, Mesonero, Francisco, Sempere, Laura, Gomollón, Fernando, Hinojosa, Joaquín, Bermejo, Fernando, Beltrán, Belén, Rodríguez-Pescador, Ainhoa, Banales, Jesús María, Olivares, David, Aguilar-Melero, Patricia, Menchén, Luis, Ferreiro-Iglesias, Rocío, Blázquez Gómez, Isabel, Benitez García, Beatriz, Guijarro, Luis G., Marin, Alicia C., Bernardo, D, Marsal, Sara, Julià Cano, Antonio, P. Gisbert, Javier, Universitat Autònoma de Barcelona. Departament de Medicina, UAM. Departamento de Medicina, [Chaparro M] Gastroenterology Unit. Hospital Universitario de La Princesa, Madrid, Spain. Instituto de Investigación Sanitaria Princesa (IIS-IP), Madrid, Spain. Universidad Autónoma de Madrid, Madrid, Spain. [Aterido A, Marsal S, Julia A] Grup de Recerca en Reumatologia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Guerra I] Gastroenterology Unit, Hospital Universitario de Fuenlabrada, Madrid, Spain. Instituto de Investigación de Hospital La Paz (IdiPaz), Madrid, Spain. [Iborra M] Gastroenterology Unit, Hospital Universitario de La Fe, Valencia, Spain. [Cabriada JL] Gastroenterology Unit, Hospital Universitario de Galdakano, Vizcaya, Spain. [Bujanda L] Gastroenterology Unit, Hospital Universitario de Donostia, San Sebastián, Spain. Instituto Biodonostia, San Sebastián, Spain. UPV/EHU, Bilbao, Spain. Ikerbasque, Bilbao, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Crohn’s disease, Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Immunologic::Receptors, Cytokine::Receptors, Tumor Necrosis Factor [CHEMICALS AND DRUGS], Necrosis, Genoma humà - Mapatge, Medicina, Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases::Crohn Disease [DISEASES], Environment and Public Health::Public Health::Epidemiologic Methods::Epidemiologic Research Design::Environment and Public Health::Public Health::Epidemiologic Methods::Genome-Wide Association Study [HEALTH CARE], Alpha (ethology), Disease, Crohn, Malaltia de, Inflammatory bowel disease, susceptibility, of-function variants, stratification, inflammatory bowel disease, adalimumab, medicine, Adalimumab, lcsh:RC799-869, aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores inmunológicos::receptores de citocinas::receptores de factores de necrosis tumoral [COMPUESTOS QUÍMICOS Y DROGAS], genes, genome, Original Research, Crohn's disease, whole-genome analysis, tumor necrosis factor alpha, business.industry, T-cells, Gastroenterology, association, Crohn’s disease, adalimumab, genes, infliximab, tumor necrosis factor alpha, whole-genome analysis, medicine.disease, Infliximab, enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal::enfermedad de Crohn [ENFERMEDADES], ambiente y salud pública::salud pública::métodos epidemiológicos::diseño de la investigación epidemiológica::ambiente y salud pública::salud pública::métodos epidemiológicos::estudio de asociación genómica completa [ATENCIÓN DE SALUD], Immunology, lcsh:Diseases of the digestive system. Gastroenterology, Tumor necrosis factor alpha, medicine.symptom, business, infliximab, polymorphisms, Factor de necrosi tumoral, medicine.drug
Abstract

Artículo escrito por un elevado número de autores, sólo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si le hubiera, y los autores pertenecientes a la UAM, The effect of low-frequency functional variation on anti-tumor necrosis factor alpha (TNF) response in Crohn’s disease (CD) patients remains unexplored. The objective of this study was to investigate the impact of functional rare variants in clinical response to anti- TNF therapy in CD. Methods: CD anti-TNF naïve patients starting anti-TNF treatment due to active disease [Crohn’s Disease Activity Index (CDAI > 150)] were included. The whole genome was sequenced using the Illumina Hiseq4000 platform. Clinical response was defined as a CDAI score, This research was funded by grants from the “Instituto de Salud Carlos III” (FIS.12/02557 and PI13/00041)

Published
2019

21. The ImageKids Study: Developing the pMEDIC and the PICMI

Author

Children's Hospital of Eastern Ontario, McMaster Children's Hospital, IWK Health Centre, Alberta Children, The Hospital for Sick Children, Children's Hospital of Philadelphia, Connecticut Children's Medical Center, Nationwide Children's Hospital, Children's Hospital Medical Center, Cincinnati, Hasbro Children's Hospital, C.S. Mott Children's Hospital, Hospital Sant Joan de Deu, Hospital Materno-Infantil de Málaga, Hôpital Necker-Enfants Malades, Erasmus Medical Center, Leiden University Medical Center, Yorkhill Hospital, Dr. von Hauner Children's Hospital, Klinikum Stuttgart, Royal Children's Hospital, Sydney Children's Hospitals Network, Sheba Medical Center, Soroka University Medical Center, Rambam Health Care Campus, Schneider Children, and Dr Dan Turner, Head of Pediatric Gastroenterology Unit

Published
2017

22. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab

Author

Laharie, D, Bourreille, A, Branche, J, Allez, M, Bouhnik, Y, Filippi, J, Zerbib, F, Savoye, G, Vuitton, L, Moreau, J, Amiot, A, Cosnes, J, Ricart, E, Dewit, Olivier, Lopez-Sanroman, A, Fumery, M, Carbonnel, F, Bommelaer, G, Coffin, B, Roblin, X, van Assche, G, Esteve, M, Farkkila, M, Gisbert, J P, Marteau, P, Nahon, S, de Vos, M, Lambert, J, Mary, J Y, Louis, E, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives, Department of Gastroenterology, Centre Hospitalier Général Cannes, Institut de Radioprotection et de Sûreté Nucléaire (IRSN), Laboratoire Électronique Ondes et Signaux pour les Transports (IFSTTAR/COSYS/LEOST), Institut Français des Sciences et Technologies des Transports, de l'Aménagement et des Réseaux (IFSTTAR)-PRES Université Lille Nord de France, Université Pierre et Marie Curie - Paris 6 (UPMC), CHU Amiens-Picardie, Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte - Clermont Auvergne (M2iSH), Institut National de la Recherche Agronomique (INRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA)-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Groupe Immunité des Muqueuses et Agents Pathogènes (GIMAP), Université Jean Monnet [Saint-Étienne] (UJM), Service de Gastroentérologie [CHU Lariboisière], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Lariboisière, Ghent University Hospital, Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Science et Ingénierie des Matériaux et Procédés (SIMaP), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-Institut National Polytechnique de Grenoble (INPG)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Institut des Maladies de l'Appareil Digestif, Université de Nantes (UN), Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Claude Huriez [Lille], CHU Lille, Hôpital Saint-Louis, Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Beaujon, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Universitaire de Nice (CHU Nice), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Hôpital de Rangueil, CHU Toulouse [Toulouse], Service d'hépato-gastro-entérologie [APHP Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service de Gastroentérologie et nutrition [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), Cliniques Universitaires Saint-Luc [Bruxelles], Hospital Universitario Ramón y Cajal [Madrid], Universidad de Alcalá - University of Alcalá (UAH), Service d'Hépato Gastroenterologie [CHU Amiens-Picardie], Hôpital Bicêtre, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, CHU Clermont-Ferrand, Hôpital Louis Mourier - AP-HP [Colombes], Service de gastroentérologie [CHU Saint-Etienne], Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), University Hospitals Leuven [Leuven], Hospital Universitario Mutua de Terrassa, University of Helsinki, Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain., Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Liège (CHU-Liège), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de la Recherche Agronomique (INRA)-Centre de Recherche en Nutrition Humaine d'Auvergne (CRNH d'Auvergne), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière, Science et Ingénierie des Matériaux et Procédés (SIMaP ), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Service d'hépato-gastroentérologie [CHU Nantes], Hôpital Claude Huriez, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'hépato-gastro-entérologie [Hôpital Saint-Louis, APHP], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Hôpital Beaujon, AP HP, Departement de Gastroenterologie et d'assistance Nutritive, Université Paris Diderot - Paris 7 (UPD7), CIC Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hépato-Gastroentérologie [Rouen], Institute for Research and Innovation in Biomedicine (IRIB), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Cliniques Universitaires Saint-Luc, UCL, 1200 Bruxelles, Belgique, parent, Service d'Hépato-gastro-entérologie [APHP Kremlin-Bicêtre], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Service d'Hépato-Gastroentérologie [CHRU Clermont-Ferrand], Centre Hospitalier Universitaire de Clermont-Ferrand, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Hopital Louis Mourier - AP-HP [Colombes], Department of Gastroenterology, Hospital Universitari Mútua de Terrassa, University of Barcelona, Terrassa. CIBEREHD, Catalonia, Spain., Helsinki University, and Helsinki University Central Hospital, Clinic of Gastroenterology, HUS, Finland., Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) y Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain., Hôpital St-Antoine, service de Gastroentérologie, Paris, France., Nutrition, Métabolisme, Aquaculture (NuMéA), Institut National de la Recherche Agronomique (INRA)-Université de Pau et des Pays de l'Adour (UPPA), Ghent University Hospital, Gent, Belgium., Department of Gastroenterology, University Hospital CHU of Liège, Liège, Belgium., Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC), UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, and UCL - (SLuc) Service de gastro-entérologie

Subjects
Adult, Male, medicine.medical_specialty, Time Factors, IBD, Drug Resistance, Azathioprine, Disease-Free Survival, 03 medical and health sciences, COLORECTAL SURGERY, 0302 clinical medicine, Refractory, Gastrointestinal Agents, Internal medicine, medicine, Humans, Cumulative incidence, Colectomy, ComputingMilieux_MISCELLANEOUS, business.industry, Gastroenterology, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, Middle Aged, medicine.disease, Ciclosporin, Ulcerative colitis, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Colorectal surgery, Infliximab, 3. Good health, Surgery, Treatment Outcome, ULCERATIVE COLITIS, 030220 oncology & carcinogenesis, Cohort, Cyclosporine, 030211 gastroenterology & hepatology, Colitis, Ulcerative, Female, Steroids, business, Immunosuppressive Agents, medicine.drug
Abstract

ObjectiveCiclosporin and infliximab have demonstrated short-term similar efficacy as second-line therapies in patients with acute severe UC (ASUC) refractory to intravenous steroids. The aim of this study was to assess long-term outcome of patients included in a randomised trial comparing ciclosporin and infliximab.DesignBetween 2007 and 2010, 115 patients with steroid-refractory ASUC were randomised in 29 European centres to receive ciclosporin or infliximab in association with azathioprine. Patients were followed until death or last news up to January 2015. Colectomy-free survival rates at 1 and 5 years and changes in therapy were estimated through Kaplan-Meier method and compared between initial treatment groups through log-rank test.ResultsAfter a median follow-up of 5.4 years, colectomy-free survival rates (95% CI) at 1 and 5 years were, respectively, 70.9% (59.2% to 82.6%) and 61.5% (48.7% to 74.2%) in patients who received ciclosporin and 69.1% (56.9% to 81.3%) and 65.1% (52.4% to 77.8%) in those who received infliximab (p=0.97). Cumulative incidence of first infliximab use at 1 and 5 years in patients initially treated with ciclosporin was, respectively, 45.7% (32.6% to 57.9%) and 57.1% (43.0% to 69.0%). Only four patients from the infliximab group were subsequently switched to ciclosporin. Three patients died during the follow-up, none directly related to UC or its treatment.ConclusionsIn this cohort of patients with steroid-refractory ASUC initially treated by ciclosporin or infliximab, long-term colectomy-free survival was independent from initial treatment. These long-term results further confirm a similar efficacy and good safety profiles of both drugs and do not favour one drug over the other.Trial registration numberEudraCT: 2006-005299-42; ClinicalTrials.gouv number: NCT00542152; post-results.

Published
2018

24. A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis

Author

Richard H. Duerr, Dalin Li, Ming-Hsi Wang, Tariq Ahmad, John D. Rioux, Patrick Sulem, Daniel B. Graham, Steven R. Brant, Severine Vermeire, Mark Tremelling, James Lee, Leena Halme, K. de Lane, Miguel Regueiro, M Parkes, David C. Wilson, Alain Bitton, R. Milgrom, Daniel G. MacArthur, Marijn C. Visschedijk, Sören Mucha, Kenneth Croitoru, Alison Simmons, Mark S. Silverberg, Rinse K. Weersma, Jonas Halfvarson, Daniel L. Rice, J. M. Stempak, Christopher J. Hawkey, Mauro D'Amato, Christopher G. Mathew, Philippe Goyette, Frauke Degenhardt, Daniel F. Gudbjartsson, Mark J. Daly, Kari Stefansson, Beryl B. Cummings, Maarit Lappalainen, Päivi Saavalainen, Paulina Paavola-Sakki, P. Fleshner, Talin Haritunians, Joshua C. Randall, Elaine R. Nimmo, Taru Tukiainen, Christine Stevens, Subra Kugathasan, Monkol Lek, Andre Franke, Kimmo Kontula, Unnur Thorsteinsdottir, Andrew Hart, Martin O. Pollard, Gabrielle Boucher, Natalie J. Prescott, Benjamin M. Neale, Holm H. Uhlig, Carl A. Anderson, Ashwin N. Ananthakrishnan, Luke Jostins, C. Mowatt, Judy H. Cho, B. Newman, A. Nicole Desch, Yang Luo, Dermot P.B. McGovern, Clara Abraham, Ingileif Jonsdottir, Jeffrey C. Barrett, John C. Mansfield, Jean-Paul Achkar, Charlie W. Lees, Martti Färkkilä, Ramnik J. Xavier, S. R. Targan, Manuel A. Rivas, Deborah D. Proctor, Johan Van Limbergen, Nicholas A. Kennedy, Christopher A. Lamb, Jürgen Glas, Vito Annese, Yashoda Sharma, Phil Schumm, Graham A. Heap, Cathryn Edwards, Lotta L. E. Koskinen, Jack Satsangi, Mitja I. Kurki, Aarno Palotie, Groningen Institute for Gastro Intestinal Genetics and Immunology (3GI), Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142, USA Analytic and Translational Genetics Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA deCODE Genetics, Amgen Inc., 101 Reykjavik, Iceland Research Center, Montreal Heart Institute, Montréal, Québec, Canada H1T1C8 School of Engineering and Natural Sciences, University of Iceland, 101 Reykjavik, Iceland Department of Immunology, Landspitali, the National University Hospital of Iceland, 101 Reykjavik, Iceland Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland Institute of Clinical Molecular Biology, Christian-Albrechts-University of Kiel, 24118 Kiel, Germany F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA Inflammatory Bowel Disease Center, Cedars-Sinai Medical Center, Los Angeles, California 90048 USA Department of Biosciences and Nutrition, Karolinska Institutet, 14183 Stockholm, Sweden BioCruces Health Research Institute and IKERBASQUE, Basque Foundation for Science, 48903 Bilbao, Spain Unit of Gastroenterology, Istituto di Ricovero e Cura a Carattere Scientifico-Casa Sollievo della Sofferenza (IRCCS-CSS) Hospital, 71013 San Giovanni Rotondo, Italy Strutture Organizzative Dipartimentali (SOD) Gastroenterologia 2, Azienda Ospedaliero Universitaria (AOU) Careggi, 50134 Florence, Italy Department of Clinical and Experimental Medicine, Translational Research in GastroIntestinal Disorders (TARGID), Katholieke Universiteit (KU) Leuven, Leuven 3000, Belgium Division of Gastroenterology, University Hospital Gasthuisberg, BE-3000 Leuven, Belgium Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, 9713 GZ Groningen, The Netherlands Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, SE 701 82 Örebro, Sweden Department of Medicine, University of Helsinki, 00100 Helsinki, Finland Helsinki University Hospital, 00100 Helsinki, Finland Clinic of Gastroenterology, Helsinki University Hospital, 00100 Helsinki, Finland Research Programs Unit, Immunobiology, and Department of Medical and Clinical Genetics, University of Helsinki, 00014 Helsinki, Finland Department of Transplantation and Liver Surgery, University of Helsinki, 00100 Helsinki, Finland Department of Medical Genetics, Biomedicum Helsinki, University of Helsinki, 00100 Helsinki, Finland Gastroenterology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA Division of Medical Sciences, Harvard Medical School, Boston, Massachusetts 02114, USA Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK IBD Pharmacogenetics, Royal Devon and Exeter NHS Trust, Exeter EX2 5DW, UK Graham A. Heap Peninsula College of Medicine and Dentistry, Exeter PL6 8BU, UK Meyerhoff Inflammatory Bowel Disease Center, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, 21205, USA Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, 21205, USA Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA Department of Human Genetics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania 15261, USA Department of Medicine, Inflammatory Bowel Disease Centre, Mount Sinai Hospital, Toronto, Ontario, Canada M5G 1X5 Department of Genetics, Yale School of Medicine, New Haven, Connecticut 06510, USA Institute for Molecular Medicine Finland, University of Helsinki, 00100 Helsinki, Finland Massachusetts General Hospital, Center for Human Genetic Research, Psychiatric and Neurodevelopmental Genetics Unit, Boston, Massachusetts 02114, USA Research Programs Unit, Immunobiology, University of Helsinki, 00100 Helsinki, Finland Faculté de Médecine, Université de Montréal, Montréal, Québec, Canada H3T 1J4 Department of Gastroenterology, Torbay Hospital, Devon, UK Department of Medicine, St. Mark’s Hospital, Middlesex, UK Nottingham Digestive Disease Centre, Queens Medical Centre, Nottingham, UK Wellcome Trust Centre for Human Genetics, University of Oxford, Headington, UK Christ Church, University of Oxford, Oxford, UK Gastrointestinal Unit, Wester General Hospital, University of Edinburgh, Edinburgh, UK Newcastle University, Newcastle upon Tyne, UK Inflammatory Bowel Disease Research Group, Addenbrooke’s Hospital, Cambridge, UK Department of Medical and Molecular Genetics, Guy’s Hospital, London, UK Department of Medical and Molecular Genetics, King’s College London School of Medicine, Guy’s Hospital, London, UK Department of Medicine, Ninewells Hospital and Medical School, Dundee, UK Genetic Medicine, Manchester Academic Health Science Centre, Manchester, UK The Manchester Centre for Genomic Medicine, University of Manchester, Manchester, UK Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, UK Translational Gastroenterology Unit, John Radcliffe Hospital, University of Oxford, Oxford, UK Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK Gastroenterology & General Medicine, Norfolk and Norwich University Hospital, Norwich, UK Translational Gastroenterology Unit and the Department of Pediatrics, University of Oxford, Oxford, UK Pediatric Gastroenterology and Nutrition, Royal Hospital for Sick Children, Edinburgh, UK Child Life and Health, University of Edinburgh, Edinburgh, UK Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA Department of Gastroenterology and Hepatology, Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio, USA Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA Division of Gastroenterology, Royal Victoria Hospital, Montréal, Québec, Canada Inflammatory Bowel Disease Group, Zane Cohen Centre for Digestive Diseases, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA Division of Pediatric Gastroenterology, Hepatology and Nutrition, Hospital for Sick Children, Toronto, Ontario, Canada Department of Public Health Sciences, University of Chicago, Chicago, Illinois, USA Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA, Department of Medicine, Clinicum, Gastroenterologian yksikkö, Immunobiology Research Program, Research Programs Unit, Department of Medical and Clinical Genetics, Medicum, II kirurgian klinikka, Department of Surgery, Institute for Molecular Medicine Finland, Aarno Palotie / Principal Investigator, Immunomics, Kimmo Kontula Research Group, and Genomics of Neurological and Neuropsychiatric Disorders

Subjects
0301 basic medicine, AAI12, Chemistry(all), SUSCEPTIBILITY LOCI, Science, Population, General Physics and Astronomy, Physics and Astronomy(all), OF-FUNCTION VARIANTS, Inflammatory bowel disease, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, NUMBER, medicine, Ring finger, IMPUTATION, Allele, education, POPULATION, RISK, education.field_of_study, Multidisciplinary, biology, Biochemistry, Genetics and Molecular Biology(all), MUTATIONS, General Chemistry, ASSOCIATION, medicine.disease, Inflammatory Bowel Diseases, Ulcerative colitis, digestive system diseases, 3. Good health, Ubiquitin ligase, Transport protein, Transmembrane domain, 030104 developmental biology, medicine.anatomical_structure, RARE VARIANTS, Immunology, biology.protein, Cancer research, 3111 Biomedicine, INFLAMMATORY-BOWEL-DISEASE
Abstract

To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files. This article is open access. Protein-truncating variants protective against human disease provide in vivo validation of therapeutic targets. Here we used targeted sequencing to conduct a search for protein-truncating variants conferring protection against inflammatory bowel disease exploiting knowledge of common variants associated with the same disease. Through replication genotyping and imputation we found that a predicted protein-truncating variant (rs36095412, p.R179X, genotyped in 11,148 ulcerative colitis patients and 295,446 controls, MAF=up to 0.78%) in RNF186, a single-exon ring finger E3 ligase with strong colonic expression, protects against ulcerative colitis (overall P=6.89 × 10(-7), odds ratio=0.30). We further demonstrate that the truncated protein exhibits reduced expression and altered subcellular localization, suggesting the protective mechanism may reside in the loss of an interaction or function via mislocalization and/or loss of an essential transmembrane domain. National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) DK064869 DK062432 National Human Genome Research Institute (NHGRI) DK064869 DK043351 HG005923 Crohns and Colitis Foundation 3765 Leona M. & Harry B. Helmsley Charitable Trust 2015PG-IBD001 Amgen 2013583217 CCFA 3765 Cedars-Sinai F. Widjaja Foundation, info:eu-repo/grantAgreement/EC/FP7/305479, European Union DK062413 AI067068 U54DE023789-01 Leona M. and Harry B. Helmsley Charitable Trust Crohn's and Colitis Foundation of America NIH DK062431 U01 DK062429 U01 DK062422 R01 DK092235 U01 DK062420 Medical Research Council, UK MR/J00314X/1 Wellcome Trust WT091310 098051 Inflammatory Bowel Disease Genetic Research Chair at the University of Pittsburgh PO1DK046763

Published
2016

26. Role of nutrition in the development and prevention of age-related hearing loss: A scoping review

Author

Miguel Ángel Rodríguez, Concepción Campos-Asensio, Irene Crespo, Luis Rodrigo, Hugo Olmedillas, Biblioteca Médica, Hospital Universitario de Getafe, Madrid, Spain., Gastroenterology Unit, Hospital Universitario Central de Asturias (HUCA), Oviedo, Spain, and Department of Functional Biology, University of Oviedo, Oviedo, Spain.

Subjects
Hearing loss, Anciano, Scopus, Dietary pattern, Nutritional Status, Age-related hearing loss, 03 medical and health sciences, 0302 clinical medicine, Estado nutricional, Environmental health, Humans, Medicine, Social isolation, Hearing Loss, Vitamin A, Aged, Nutrition, Hypoacusis, chemistry.chemical_classification, lcsh:R5-920, business.industry, Nutritional status, Vitamins, General Medicine, Diet, chemistry, Pérdida auditiva, 030220 oncology & carcinogenesis, Dieta, 030211 gastroenterology & hepatology, medicine.symptom, lcsh:Medicine (General), business, Polyunsaturated fatty acid
Abstract

Age-related hearing loss (ARHL) is a major and increasingly prevalent health problem worldwide, causing disability and social isolation in the people who present it. This impairment is caused by genetic and environmental factors. Nutritional status has been identified as a related risk associated with hearing loss (HL). This scoping review aimed to characterize the links between HL and nutritional status. PubMed, Embase, Cochrane and Scopus databases were searched up to December 2019. Studies examining the relation between nutrition and dietary habits and HL were included. After screening 3510 citations, 22 publications were selected for inclusion in the current review, all of which were published between 2010 and 2019. Diets rich in saturated fats and cholesterol have deleterious effects on hearing that could be prevented by lower consumption. Conversely, greater consumption of fruit and vegetables, and of polyunsaturated fatty acids (omega-3) and anti-oxidants in the form of vitamins A, C, and E, prevent the development of ARHL. The current literature suggests a possible association between nutritional status and hearing loss. More studies are needed to better characterize the clinical consequences of this association. Sí

Published
2021

27. Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response

Author

Azzi, Jessica, Dorival, Céline, Cagnot, Carole, Fontaine, Hélène, Lusivika-Nzinga, Clovis, Leroy, Vincent, de Ledinghen, Victor, Tran, Albert, Zoulim, Fabien, Alric, Laurent, Gournay, Jérôme, Bronowicki, Jean-Pierre, Decaens, Thomas, Riachi, Ghassan, Mikhail, Nabiel, Soliman, Reham, Shiha, Gamal, Pol, Stanislas, Carrat, Fabrice, Ganne-Carrié, Nathalie, Hepather, Anrs-Afef, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), ANRS France Recherche Nord & sud Sida-hiv hépatites, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hépato-gastro-entérologie [APHP Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Bordeaux Research In Translational Oncology [Bordeaux] (BaRITOn), Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Nice (CHU Nice), Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Hospices Civils de Lyon, Departement de Neurologie (HCL), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre hospitalier universitaire de Nantes (CHU Nantes), Imagerie Adaptative Diagnostique et Interventionnelle (IADI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire [Grenoble] (CHU), Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU), Assiut University, Port Said University, Mansoura University [Egypt], Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), AP-HP - Hôpitaux Universitaires Paris Seine-Saint-Denis (GHU 93), INSERM U1053, Université Bordeaux, Bordeaux, France., Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Purpan (CHU Purpan), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Inserm U1254, Centre Hospitalier Universitaire de Nancy (CHU Nancy), Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt, Biostatistics and Cancer Epidemiology Department, South Egypt Cancer Institute, Assiut University, Assuit, Egypt., Tropical Medicine Department, Faculty of Medicine, Port Said University, Port Said, Egypt., Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt., Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), École pratique des hautes études (EPHE), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC), and Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPC)

Subjects
Liver Cirrhosis, Male, Carcinoma, Hepatocellular, Hepatology, Sustained Virologic Response, Hepatitis C virus, Liver Neoplasms, Gastroenterology, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, [SDV.CAN]Life Sciences [q-bio]/Cancer, Hepacivirus, Hepatitis C, Chronic, Middle Aged, Antiviral Agents, Hepatitis C, Risk factors, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Humans, Risk score, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, HCC, ComputingMilieux_MISCELLANEOUS
Abstract

International audience; Background & Aims: Prediction of hepatocellular carcinoma (HCC) occurrence in patients with chronic hepatitis C (HCV) who achieved a sustained virological response (SVR) after direct acting antivirals (DAAs) remains challenging.Methods: Among HCC-free HCV patients with advanced fibrosis enrolled in the ANRS CO22 HEPATHER cohort who achieved SVR 12 weeks after treatment with DAAs, HCC predictive models were developed using Cox multivariable regression. The derived score was externally validated in a large Egyptian cohort. Our main outcome was the HCC-free survival.Results: During follow-up (median 3.05 years), 153 out of 3531 patients developed a HCC. Main variables associated with HCC occurrence were: male gender, HCV genotype 3, esophageal varices, albumin < 40 g/L, total bilirubin >11 µmol/L and hypercholesterolemia before DAA initiation, together with age > 58 years, FIB-4 index ≥3.25 evaluated at SVR. A score was established allowing the stratification of patients by high (score ≥ 12/22), intermediate (7 ≤ score

Published
2022

28. Accurate and timely diagnosis of eosinophilic esophagitis improves over time in Europe: an analysis of the EoE CONNECT Registry

Author

Pilar Navarro, Emilio J Laserna‐Mendieta, Sergio Casabona, Edoardo Savarino, María Teresa Pérez‐Fernández, Matteo Ghisa, Isabel Pérez‐Martínez, Danila Guagnozzi, Antonia Perelló, Antonio Guardiola‐Arévalo, Francesca Racca, Elena Betoré, Leonardo Blas‐Jhon, Anne Lund Krarup, Verónica Martín‐Domínguez, Daria Maniero, Adolfo Suárez, Ronald Llerena‐Castro, Luisa de la Peña‐Negro, Alicia Granja Navacerrada, Gaia Pellegatta, Javier Alcedo, Lonore de Hurtado Mendoza‐Guena, Sara Feo‐Ortega, Jesús Barrio, Carolina Gutiérrez‐Junquera, Sonia Fernández‐Fernández, Susana De la Riva, Juan E Navés, Silvia Carrión, Constanza Ciriza de los Ríos, Natalia García‐Morales, Juan Armando Rodríguez‐Oballe, Raffaela Dainese, Alba Rodríguez‐Sánchez, María Lluisa Masiques‐Mas, María Teresa Palomeque, Cecilio Santander, Sonsoles Tamarit‐Sebastián, Ángel Arias, Alfredo J Lucendo, [Navarro P] Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, Spain. Instituto de Investigación Sanitaria La Princesa, Madrid, Spain. Instituto de Investigación Sanitaria de Castilla‐La Mancha (IDISCAM), Tomelloso, Spain. [Laserna-Mendieta EJ] Department of Gastroenterology, Hospital General de Tomelloso, Tomelloso, Spain. Instituto de Investigación Sanitaria La Princesa, Madrid, Spain. Instituto de Investigación Sanitaria de Castilla‐La Mancha (IDISCAM), Tomelloso, Spain. Laboratory Medicine Department. Hospital Universitario de La Princesa, Madrid, Spain. [Casabona S, Pérez-Fernández MT] Instituto de Investigación Sanitaria La Princesa, Madrid, Spain. Department of Gastroenterology, Hospital Universitario de La Princesa, Madrid, Spain. [Savarino E, Ghisa M] Department of Surgery, Oncology and Gastroenterology, Gastroenterology Unit, Azienza Ospedaliera di Padova, Padova, Italy. [Masiques-Mas ML] Department of Pediatric Gastroenterology, Hospital General de Granollers, Granollers, Spain, and Hospital General de Granollers

Subjects
Gastrointestinal, Digestive System Diseases::Gastrointestinal Diseases::Esophageal Diseases::Esophagitis::Eosinophilic Esophagitis [DISEASES], Delayed Diagnosis, administración de los servicios de salud::calidad de la atención sanitaria::garantía de calidad de la atención sanitaria::directrices como asunto::guías de práctica clínica como asunto [ATENCIÓN DE SALUD], Deglutition Disorders/diagnosis, diagnóstico::técnicas y procedimientos diagnósticos::técnicas diagnósticas quirúrgicas::endoscopia [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Diagnòstic, Health Services Administration::Quality of Health Care::Quality Assurance, Health Care::Guidelines as Topic::Practice Guidelines as Topic [HEALTH CARE], Eosinophilia, Humans, Registries, Endoscòpia, Diagnostic delay, Endoscopy, Eosinophilic esophagitis, Guideline Adherence, Practice Guidelines as Topic, Cross-Sectional Studies, Enteritis, Gastritis, Deglutition Disorders, Eosinophilic Esophagitis, Gastroenterology, Reflux gastroesofàgic, enfermedades del sistema digestivo::enfermedades gastrointestinales::enfermedades del esófago::esofagitis::esofagitis eosinofílica [ENFERMEDADES], Oncology, Eosinophilic Esophagitis/diagnosis, Diagnosis::Diagnostic Techniques and Procedures::Diagnostic Techniques, Surgical::Endoscopy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT]
Abstract

Diagnostic delay; Endoscopy; Eosinophilic esophagitis Retraso en el diagnóstico; Endoscopia; Esofagitis eosinofílica Retard diagnòstic; Endoscòpia; Esofagitis eosinofílica Background: Poor adherence to clinical practice guidelines for eosinophilic esophagitis (EoE) has been described and the diagnostic delay of the disease continues to be unacceptable in many settings. Objective: To analyze the impact of improved knowledge provided by the successive international clinical practice guidelines on reducing diagnostic delay and improving the diagnostic process for European patients with EoE. Methods: Cross-sectional analysis of the EoE CONNECT registry based on clinical practice. Time periods defined by the publication dates of four major sets of guidelines over 10 years were considered. Patients were grouped per time period according to date of symptom onset. Results: Data from 1,132 patients was analyzed and median (IQR) diagnostic delay in the whole series was 2.1 (0.7-6.2) years. This gradually decreased over time with subsequent release of new guidelines (p < 0.001), from 12.7 years up to 2007 to 0.7 years after 2017. The proportion of patients with stricturing of mixed phenotypes at the point of EoE diagnosis also decreased over time (41.3% vs. 16%; p < 0.001), as did EREFS scores. The fibrotic sub-score decreased from a median (IQR) of 2 (1-2) to 0 (0-1) when patients whose symptoms started up to 2007 and after 2017 were compared (p < 0.001). In parallel, symptoms measured with the Dysphagia Symptoms Score reduced significantly when patients with symptoms starting before 2007 and after 2012 were compared. A reduction in the number of endoscopies patients underwent before the one that achieved an EoE diagnosis, and the use of allergy testing as part of the diagnostic workout of EoE, also reduced significantly over time (p = 0.010 and p < 0.001, respectively). Conclusion: The diagnostic work-up of EoE patients improved substantially over time at the European sites contributing to EoE CONNECT, with a dramatic reduction in diagnostic delay.

Published
2022

29. Micronutrient Deficiencies in Patients with Decompensated Liver Cirrhosis

Author

Meritxell Casas, Gemma Llibre-Nieto, Jordi Sánchez-Delgado, Mireia Miquel, Antonia Humanes, Alba Lira, Cristina Solé, Gemma Solé, Laia Grau, Mercedes Vergara, Josep Maria Barradas, Valentí Puig-Diví, [Llibre-Nieto G] Hepatology Unit, Digestive Disease Department, Hospital Universitari Parc Tauli, Institut d’Investigació i Innovació Parc Taulí (I3PT), Sabadell, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Hospital General de Granollers, Granollers, Spain. [Lira A, Casas M] Hepatology Unit, Digestive Disease Department, Hospital Universitari Parc Tauli, Institut d’Investigació i Innovació Parc Taulí (I3PT), Sabadell, Spain. [Vergara M] Hepatology Unit, Digestive Disease Department, Hospital Universitari Parc Tauli, Institut d’Investigació i Innovació Parc Taulí (I3PT), Sabadell, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. [Solé C] Hepatology Unit, Digestive Disease Department, Hospital Universitari Parc Tauli, Institut d’Investigació i Innovació Parc Taulí (I3PT), Sabadell, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. [Puig-Diví V] Hepatology Unit, Digestive Disease Department, Hospital Universitari Parc Tauli, Institut d’Investigació i Innovació Parc Taulí (I3PT), Sabadell, Spain. Gastroenterology Unit, Digestive Disease Department, Hospital Universitari Parc Tauli, Institut d’Investigacio i Innovació Parc Taulí (I3PT), Sabadell, Spain, and Hospital General de Granollers

Subjects
Liver Cirrhosis, Male, Micronutrient deficiency, Cirrhosis, medicine.medical_treatment, decompensated cirrhosis, enfermedades del sistema digestivo::enfermedades hepáticas::cirrosis hepática [ENFERMEDADES], Digestive System Diseases::Liver Diseases::Liver Cirrhosis [DISEASES], Severity of Illness Index, Gastroenterology, Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Growth Substances::Nutrients::Micronutrients [CHEMICALS AND DRUGS], chemistry.chemical_compound, 0302 clinical medicine, Risk Factors, Prevalence, Micronutrients, Prospective Studies, Nutrition and Dietetics, trace element deficiency, Middle Aged, Micronutrient, enfermedades nutricionales y metabólicas::trastornos nutricionales::desnutrición::enfermedades carenciales::avitaminosis [ENFERMEDADES], 030220 oncology & carcinogenesis, vitamin deficiency, Female, 030211 gastroenterology & hepatology, acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::sustancias del crecimiento::nutrientes::micronutrientes [COMPUESTOS QUÍMICOS Y DROGAS], lcsh:Nutrition. Foods and food supply, Nutritional and Metabolic Diseases::Nutrition Disorders::Malnutrition::Deficiency Diseases::Avitaminosis [DISEASES], Vitamin, medicine.medical_specialty, Cirrosi hepàtica, lcsh:TX341-641, malnutrition, Malnutrició, Article, End Stage Liver Disease, 03 medical and health sciences, micronutrient deficiency, Internal medicine, medicine, Vitamin D and neurology, Avitaminosi, Humans, Decompensation, Vitamin B12, Aged, business.industry, Vitamin E, medicine.disease, chemistry, business, Food Science
Abstract

Patients with cirrhosis often develop malnutrition and micronutrient deficiencies, leading to a worse prognosis and increased mortality. Our main goal was to assess the prevalence of micronutrient deficiencies in patients with decompensated cirrhosis. This was a prospective single-center study including 125 consecutive patients hospitalized for acute decompensation of cirrhosis (mostly of alcoholic etiology). A blood test including trace elements and vitamins was performed on admission. The main micronutrient deficiencies observed were vitamin D (in 94.5%), vitamin A (93.5%), vitamin B6 (60.8%) and zinc (85.6%). Patients in Child-Pugh class C had lower levels of vitamin A (p &lt, 0.0001), vitamin E (p = 0.01) and zinc (p &lt, 0.001), and higher levels of ferritin (p = 0.002) and vitamin B12 (p &lt, 0.001) than those in Child-Pugh class A and B. Patients with a higher model of end-stage liver disease (MELD) score had lower levels of vitamin A (p &lt, 0.0001), vitamin E (p &lt, 0.001), magnesium (p = 0.01) and zinc (p = 0.001), and higher levels of ferritin (p = 0.002) and vitamin B12 (p &lt, 0.0001). Severe hepatic insufficiency correlated with lower levels of zinc, vitamin E and vitamin A, and higher levels of vitamin B12 and ferritin.

Published
2021
Full Text
View/download PDF

30. In Patients With Obesity, the Number of Adipose Tissue Mast Cells Is Significantly Lower in Subjects With Type 2 Diabetes

Author

David Lopez-Perez, Anaïs Redruello-Romero, Jesús Garcia-Rubio, Carlos Arana, Luis A. Garcia-Escudero, Francisco Tamayo, Jose D. Puentes-Pardo, Sara Moreno-SanJuan, Javier Salmeron, Armando Blanco, Julio Galvez, Josefa Leon, Ángel Carazo, [Lopez-Perez,D, Puentes-Pardo,JD, Galvez,J] Department of Pharmacology, Faculty of Pharmacy, University of Granada, Granada, Spain. [Lopez-Perez,D, Redruello-Romero,A, Galvez,J, Leon,J, Carazo,A] Research Unit, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain. [Garcia-Rubio,J, Tamayo,F] Surgery Unit, San Cecilio University Hospital, Granada, Spain. [Arana,C] Endocrinology and Nutrition Unit, Virgen de las Nieves University Hospital, Granada, Spain. [García-Escuder,LA] Department of Statistics and Operative Research, Faculty of Sciences, University of Valladolid, Valladolid, Spain. [Moreno-SanJuan,S] Cytometry and Microscopy Research Service, Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain. [Salmeron,J] Gastroenterology Unit, San Cecilio University Hospital, Granada, Spain. [Blanco,A] Department of Computer Science and Artificial Intelligence, University of Granada, Granada, Spain. [Galvez,J] Centro de Investigación Biomédica En Red para Enfermedades Hepáticas y Digestivas (CIBER-EHD), Center for Biomedical Research, University of Granada, Granada, Spain. [Leon,J, Carazo,A] Clinical Management Unit of Digestive Disease, San Cecilio University Hospital, Granada, Spain., and Instituto de Salud Carlos III (grant PI18/01947). Instituto de Salud Carlos III is a research institution from the Spanish government that funds biomedical research. Instituto de Salud Carlos III funded all the experiments.

Subjects
0301 basic medicine, obesity, endocrine system diseases, Angiogenesis, Obesidad, Phenomena and Processes::Cell Physiological Phenomena::Cell Physiological Processes::Cell Differentiation::Adipogenesis [Medical Subject Headings], Mastocitos, Adipose tissue, Cell Count, White adipose tissue, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], angiogenesis, 0302 clinical medicine, Phenomena and Processes::Circulatory and Respiratory Physiological Phenomena::Cardiovascular Physiological Phenomena::Cardiovascular Physiological Processes::Neovascularization, Physiologic [Medical Subject Headings], Immunology and Allergy, T2D, Flow cytometry, Mast Cells, Intestinal Mucosa, Original Research, education.field_of_study, Adipogenesis, food and beverages, Mast cell, Anatomy::Tissues::Connective Tissue::Adipose Tissue [Medical Subject Headings], adipose tissue, medicine.anatomical_structure, Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus, Type 2 [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Immunologic Tests::Immunophenotyping [Medical Subject Headings], lipids (amino acids, peptides, and proteins), medicine.symptom, hormones, hormone substitutes, and hormone antagonists, Tejido adiposo, medicine.medical_specialty, Adipose Tissue, White, Population, Immunology, Neovascularization, Physiologic, 030209 endocrinology & metabolism, Inflammation, Anatomy::Cells::Connective Tissue Cells::Mast Cells [Medical Subject Headings], Immunophenotyping, 03 medical and health sciences, Internal medicine, Chemicals and Drugs::Biological Factors::Biological Markers [Medical Subject Headings], medicine, Humans, Obesity, Progenitor cell, education, Inflamación, business.industry, flow cytometry, nutritional and metabolic diseases, RC581-607, Diseases::Nutritional and Metabolic Diseases::Nutrition Disorders::Overnutrition::Obesity [Medical Subject Headings], Anatomy::Tissues::Connective Tissue::Adipose Tissue::Adipose Tissue, White [Medical Subject Headings], 030104 developmental biology, Endocrinology, Diabetes Mellitus, Type 2, inflammation, Immunologic diseases. Allergy, Citometría de flujo, business, mast cell, Anatomy::Digestive System::Gastrointestinal Tract::Intestines::Intestinal Mucosa [Medical Subject Headings], Biomarkers
Abstract

This work was supported by Instituto de Salud Carlos III (grant PI15/01361), Spain; and MINECO (grant DPI2017-84439-R), Madrid and FEDER. DL-P is a predoctoral fellow ("Programa de doctorado en Bioquimica y Biologia Molecular", B16.56.1) funded by the Spanish Ministry of Science and Innovation (" Formacion de profesorado universitario" grant FPU18/ 04432). DL-P participated in this work thanks to a grant from University of Granada ("Becas de iniciacion a la investigacion del plan propio de la UGR")., Type 2 diabetes (T2D) is a rising global health problem mainly caused by obesity and a sedentary lifestyle. In healthy individuals, white adipose tissue (WAT) has a relevant homeostatic role in glucose metabolism, energy storage, and endocrine signaling. Mast cells contribute to these functions promoting WAT angiogenesis and adipogenesis. In patients with T2D, inflammation dramatically impacts WAT functioning, which results in the recruitment of several leukocytes, including monocytes, that enhance this inflammation. Accordingly, the macrophages population rises as the WAT inflammation increases during the T2D status worsening. Since mast cell progenitors cannot arrive at WAT, the amount of WAT mast cells depends on how the new microenvironment affects progenitor and differentiated mast cells. Here, we employed a flow cytometry-based approach to analyze the number of mast cells from omental white adipose tissue (o-WAT) and subcutaneous white adipose tissue (s-WAT) in a cohort of 100 patients with obesity. Additionally, we measured the number of mast cell progenitors in a subcohort of 15 patients. The cohort was divided in three groups: non-T2D, pre-T2D, and T2D. Importantly, patients with T2D have a mild condition (HbA1c, Instituto de Salud Carlos III PI15/01361, MINECO, Madrid DPI2017-84439-R, European Commission, Spanish Ministry of Science and Innovation (" Formacion de profesorado universitario" grant) FPU18/04432 B16.56.1, University of Granada ("Becas de iniciacion a la investigacion del plan propio de la UGR")

Published
2021

32. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease

Author

Marco Enea, Vincent Wai-Sun Wong, Aline Keyrouz, Anna Ludovica Fracanzani, Antonio Craxì, Sergio Mazzola, Javier Ampuero, Mauro Viganò, Jérôme Boursier, Salvatore Petta, Ramy Younes, Victor de Ledinghen, Annalisa Berzigotti, Giada Sebastiani, Manuel Romero-Gómez, Marraud des Grottes, Calogero Cammà, Elisabetta Bugianesi, Vito Di Marco, Yuly P. Mendoza, Grazia Pennisi, Fonds de Recherche du Québec, McGill University, I Gastroenterology Unit, Department of Medicine, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Università degli studi di Palermo - University of Palermo, Salvatore Petta, Giada Sebastiani, Mauro Viganò, Javier Ampuero, Vincent Wai-Sun Wong, Jerome Boursier, Annalisa Berzigotti, Elisabetta Bugianesi, Anna Ludovica Fracanzani, Calogero Cammà, Marco Enea, Marraud des Grotte, Vito Di Marco, Ramy Youne, Aline Keyrouz, Sergio Mazzola, Yuly Mendoza, Grazia Pennisi, Manuel Romero-Gomez, Antonio Craxì, and Victor de Ledinghen

Subjects
Liver Cirrhosis, medicine.medical_specialty, Carcinoma, Hepatocellular, Settore MED/09 - Medicina Interna, NASH, cACLD, prognostic factor, steatohepatitis, [SDV]Life Sciences [q-bio], Prognostic Factor, Steatohepatitis, Gastrointestinal Hemorrhage, Humans, Liver, Retrospective Studies, Elasticity Imaging Techniques, Esophageal and Gastric Varices, Liver Neoplasms, Non-alcoholic Fatty Liver Disease, 610 Medicine & health, Chronic liver disease, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Interquartile range, Internal medicine, Ascites, Nonalcoholic fatty liver disease, medicine, ComputingMilieux_MISCELLANEOUS, Hepatology, business.industry, steatohepatiti, Carcinoma, Hazard ratio, Hepatocellular, medicine.disease, 3. Good health, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, 030211 gastroenterology & hepatology, medicine.symptom, Transient elastography, business
Abstract

[Background & Aims] Patients with advanced fibrosis related to nonalcoholic fatty liver disease (NAFLD) are at risk of developing hepatic and extrahepatic complications. We investigated whether, in a large cohort of patients with NAFLD and compensated advanced chronic liver disease, baseline liver stiffness measurements (LSMs) and their changes can be used to identify patients at risk for liver-related and extrahepatic events., [Methods] We performed a retrospective analysis of consecutive patients with NAFLD (n = 1039) with a histologic diagnosis of F3–F4 fibrosis and/or LSMs>10 kPa, followed for at least 6 months, from medical centers in 6 countries. LSMs were made by FibroScan using the M or XL probe and recorded at baseline and within 1 year from the last follow-up examination. Differences between follow up and baseline LSMs were categorized as: improvement (reduction of more than 20%), stable (reduction of 20% to an increase of 20%), impairment (an increase of 20% or more). We recorded hepatic events (such as liver decompensation, ascites, encephalopathy, variceal bleeding, jaundice, or hepatocellular carcinoma [HCC]) and overall and liver-related mortality during a median follow-up time of 35 months (interquartile range, 19–63 months)., [Results] Based on Cox regression analysis, baseline LSM was independently associated with occurrence of hepatic decompensation (hazard ratio [HR], 1.03; 95% CI, 1.02–1.04; P < .001), HCC (HR, 1.03; 95% CI, 1.00–1.04; P = .003), and liver-related death (HR, 1.02; 95% CI, 1.02–1.03; P = .005). In 533 patients with available LSMs during the follow-up period, change in LSM was independently associated with hepatic decompensation (HR, 1.56; 95% CI, 1.05–2.51; P = .04), HCC (HR, 1.72; 95% CI, 1.01–3.02; P = .04), overall mortality (HR, 1.73; 95% CI, 1.11–2.69; P = .01), and liver-related mortality (HR, 1.96; 95% CI, 1.10–3.38; P = .02)., [Conclusions] In patients with NAFLD and compensated advanced chronic liver disease, baseline LSM and change in LSM are associated with risk of liver-related events and mortality., Giada Sebastiani is supported by a Junior 1 and 2 Salary Award from Fonds de Recherche Santé du Québec (#27127 and #267806) and research salary from the Department of Medicine of McGill University.

Published
2021

33. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic

Author

Boettler, Tobias, Marjot, Thomas, Newsome, Philip N, Mondelli, Mario U, Maticic, Mojca, Cordero, Elisa, Jalan, Rajiv, Moreau, Richard, Cornberg, Markus, Berg, Thomas, and [Boettler,T] Department of Medicine II, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. [Marjot,T] Oxford Liver Unit, Translational Gastroenterology Unit, Oxford University Hospitals NHS Foundation Trust, University of Oxford, UK. [Newsome,PN] National Institute for Health Research, Birmingham Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. [Newsome,PN] Centre for Liver & Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. [Mondelli,MU] Division of Infectious Diseases and Immunology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy. [Maticic,M] Clinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana, Slovenia. [Maticic,M] Faculty of Medicine, University of Ljubljana, Slovenia. [Cordero,E] Department of Medicine, University of Seville, Clinical Unit of Infectious Diseases University Hospital Virgen del Rocio, Institute of Biomedicine, Sevilla, CSIC, Spain. [Jalan,R] Liver Failure Group, Institute for Liver and Digestive Health, University College London, London, UK. [Moreau,R] Inserm, Université de Paris, U1149, Centre de Recherche sur l'Inflammation (CRI), UMRS1149, Paris, France. [Moreau,R] Service d'Hépatologie, Hôpital Beaujon, Assistance Publique-Hôpitaux de Paris, Clichy, France. [Cornberg,M] Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. [Cornberg,M] Centre for Individualised Infection Medicine (CIIM), Hannover, Germany. [Berg,T] Division of Hepatology, Department of Medicine II, Leipzig University Medical Center, Leipzig, Germany.

Subjects
Transplantation, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Surgical Procedures, Operative::Digestive System Surgical Procedures::Liver Transplantation [Medical Subject Headings], Hígado, Anatomy::Digestive System::Liver [Medical Subject Headings], Infecciones por coronavirus, COVID-19, Diseases::Digestive System Diseases::Liver Diseases::Liver Cirrhosis [Medical Subject Headings], Cirrosis hepática, Enfermedad del hígado graso no alcohólico, Telemedicina, Diseases::Neoplasms [Medical Subject Headings], Telemedicine, Neoplasias, Diseases::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [Medical Subject Headings], Information Science::Information Science::Communications Media::Telecommunications::Telemedicine [Medical Subject Headings], Liver, Cirrhosis, NAFLD, Transplante, Pandemics, Cancer, Pandemias
Abstract

During the early stages of the coronavirus disease 2019 (COVID-19) pandemic, EASL and ESCMID published a position paper to provide guidance for physicians involved in the care of patients with chronic liver disease. While some healthcare systems are returning to a more normal routine, many countries and healthcare systems have been, or still are, overwhelmed by the pandemic, which is significantly impacting on the care of these patients. In addition, many studies have been published focusing on how COVID-19 may affect the liver and how pre-existing liver diseases might influence the clinical course of COVID-19. While many aspects remain poorly understood, it has become increasingly evident that pre-existing liver diseases and liver injury during the disease course must be kept in mind when caring for patients with COVID-19. This review should serve as an update on the previous position paper, summarising the evidence for liver disease involvement during COVID-19 and providing recommendations on how to return to routine care wherever possible. Yes

Published
2020

34. Reflex testing. A key tool for the elimination of hepatitis C

Author

Herrero, José Ignacio, Ampuero, Javier, Fernández-Rodríguez, Conrado M., and [Herrero,JI] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd). Instituto de Investigación Sanitaria de Navarra (IdiSNA). Clínica Universidad de Navarra. Pamplona, Spain. [Ampuero,J] Unit for the Clinical Management of Digestive Diseases. Hospital Universitario Virgen del Rocío. Lab. 213. Instituto de Biomedicina de Sevilla (IBIS). Department of Medicine. Universidad de Sevilla. Centro de Investigación Biomédica en Red de Enfermedades. Hepáticas y Digestivas (CIBERehd). Instituto de Biomedicina de Sevilla (IBIS). Hospital Universitario Virgen del Rocío. Sevilla, Spain. [Fernández,C] Gastroenterology Unit. Hospital Universitario Fundación Alcorcón. Universidad Rey Juan Carlos. Alcorcón, Madrid. Spain.

Subjects
ComputingMilieux_THECOMPUTINGPROFESSION, Diseases::Virus Diseases::Hepatitis, Viral, Human::Hepatitis C::Hepatitis C, Chronic [Medical Subject Headings], Diseases::Neoplasms::Neoplasms by Site::Digestive System Neoplasms::Liver Neoplasms [Medical Subject Headings], Diseases::Digestive System Diseases::Liver Diseases::Liver Cirrhosis [Medical Subject Headings], Diseases::Virus Diseases::Hepatitis, Viral, Human::Hepatitis C [Medical Subject Headings], Cirrosis hepática, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Clinical Laboratory Techniques [Medical Subject Headings], Hepatitis C, Neoplasias hepáticas, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [Medical Subject Headings], TheoryofComputation_MATHEMATICALLOGICANDFORMALLANGUAGES, Liver neoplasms, Liver cirrhosis, Reflex
Abstract

Yes

Published
2020

35. Biophysical and lipidomic biomarkers of cardiac remodeling post-myocardial infarction in humans

Author

Samouillan, Valérie, Martinez de Lejarza Samper, Ignacio Miguel, Benitez Amaro, Aleyda, Vilades, David, Dandurand, Jany, Casas, Josefina, Jorge, Esther, de Gonzalo Calvo, David, Gallardo, Alberto, Lerma, Enrique, Guerra, Jose Maria, Carreras, Francesc, Leta, Ruben, Llorente Cortes, Vicenta, Centre interuniversitaire de recherche et d'ingenierie des matériaux (CIRIMAT), Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC), Universitat Autònoma de Barcelona (UAB), Cardiology department Hospital Universitario La Paz. UAM. IdiPaz. CIBER-CV, Madrid, Spain, Institute of Biomedical Research of Barcelona of the Spanish National Research Council (IIBB-CSIC), Hospital de la Santa Creu i Sant Pau, Institute for Advanced Chemistry of Catalonia, Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP), Universidad Autónoma de Madrid and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain., Centre National de la Recherche Scientifique - CNRS (FRANCE), Institute of Biomedical Research of Barcelona of the Spanish National Research Council - IIBB-CSIC (SPAIN), Institut National Polytechnique de Toulouse - Toulouse INP (FRANCE), Université Toulouse III - Paul Sabatier - UT3 (FRANCE), Universitat Autònoma de Barcelona - UAB (SPAIN), Hospital de la Santa Creu i Sant Pau (SPAIN), Instituto de Salud Carlos III - ISC (SPAIN), and Institut de Química Avançada de Catalunya - IQAC (SPAIN)

Subjects
Male, Ventricular Remodeling, Matériaux, Myocardial Infarction, lcsh:QR1-502, technology, industry, and agriculture, Cardiac remodeling post-MI, Fourier transform infrared spectroscopy, Heart failure, [CHIM.MATE]Chemical Sciences/Material chemistry, Middle Aged, Article, lcsh:Microbiology, Biophysical markers, Lipidomics, Humans, Female, lipids (amino acids, peptides, and proteins), Biomarkers
Abstract

Few studies have analyzed the potential of biophysical parameters as markers of cardiac remodeling post-myocardial infarction (MI), particularly in human hearts. Fourier transform infrared spectroscopy (FTIR) illustrates the overall changes in proteins, nucleic acids and lipids in a single signature. The aim of this work was to define the FTIR and lipidomic pattern for human left ventricular remodeling post-MI. A total of nine explanted hearts from ischemic cardiomyopathy patients were collected. Samples from the right ventricle (RV), left ventricle (LV) and infarcted left ventricle (LV INF) were subjected to biophysical (FTIR and differential scanning calorimetry, DSC) and lipidomic (liquid chromatography–high-resolution mass spectrometry, LC–HRMS) studies. FTIR evidenced deep alterations in the myofibers, extracellular matrix proteins, and the hydric response of the LV INF compared to the RV or LV from the same subject. The lipid and esterified lipid FTIR bands were enhanced in LV INF, and both lipid indicators were tightly and positively correlated with remodeling markers such as collagen, lactate, polysaccharides, and glycogen in these samples. Lipidomic analysis revealed an increase in several species of sphingomyelin (SM), hexosylceramide (HexCer), and cholesteryl esters combined with a decrease in glycerophospholipids in the infarcted tissue. Our results validate FTIR indicators and several species of lipids as useful markers of left ventricular remodeling post-MI in humans., This work was supported by grants from the Fundació La MARATÓ de TV3 (201516_10) and Fondo de Investigación Sanitaria, Instituto de Salud Carlos III (FIS PI18/01584 (to V.L.C..) and PI20/01702 (to J.M.G.R.) cofunded by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER). CIBER Cardiovascular (CV) and CIBER Enfermedades Hepáticas y digestivas (EHD) are Instituto de Salud Carlos III Projects.

Published
2020

36. The methylome of the celiac intestinal epithelium harbours genotype-independent alterations in the HLA region

Author

Nora Fernandez-Jimenez, Leticia Plaza-Izurieta, Vincent Cahais, Iñaki Irastorza, Irati Romero-Garmendia, Maria Legarda, D Degli Esposti, Zdenko Herceg, Koldo Garcia-Etxebarria, Jose Ramon Bilbao, Szilvia Ecsedi, Amaia Jauregi-Miguel, Cyrille Cuenin, Ainara Castellanos-Rubio, Hector Hernandez-Vargas, Epigenetics Group, International Agency for Research on Cancer (IARC), Department of Genetics, Physical Anthropology and Animal Physiology, Biocruces-Bizkaia Health Research Institute, University of the Basque Country [Bizkaia] (UPV/EHU)-University of the Basque Country [Bizkaia] (UPV/EHU)-Biocruces-Bizkaia Health Research Institute, University of the Basque Country [Bizkaia] (UPV/EHU)-University of the Basque Country [Bizkaia] (UPV/EHU), Department of Gastrointestinal and Liver Diseases, Biodonostia Health Research Institute, Pediatric Gastroenterology Unit, Hospital Universitario Cruces = Cruces University Hospital, Institut de Biologie Valrose (IBV), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), Spanish Biomedical Research Center in Diabetes and associated Metabolic Disorders (CIBERDEM), Milieux aquatiques, écologie et pollutions (UR MALY), Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), Department of Immunology, Virology and Inflammation, TGF beta and Immune Evasion Group, Cancer Research Center of Lyon, Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS)-Cancer Research Center of Lyon, Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Leon Berard Hospital, ISCIII Research Project PI13/01201PI16/00258European Union ERDF/ESF - Spanish Ministry of Economy and Competitiveness European Union (EU) Basque Government2011/111034IARC Basque Department of Education University of Basque Country IARC Postdoctoral Fellowship program, Cruces University Hospital, COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015 - 2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), University of the Basque Country/Euskal Herriko Unibertsitatea (UPV/EHU)-University of the Basque Country/Euskal Herriko Unibertsitatea (UPV/EHU)-Biocruces-Bizkaia Health Research Institute, University of the Basque Country/Euskal Herriko Unibertsitatea (UPV/EHU)-University of the Basque Country/Euskal Herriko Unibertsitatea (UPV/EHU), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), and Lallemant, Christopher

Subjects
Male, 0301 basic medicine, lymphocytes, Biopsy, epigenome, dna methylation, Expression, Associations, Epigenome, [SPI]Engineering Sciences [physics], 0302 clinical medicine, HLA Antigens, Mechanisms, Lymphocytes, Intestinal Mucosa, Promoter Regions, Genetic, Cancer, Genetics, mechanisms, Multidisciplinary, Methylation, Wide Analysis, 3. Good health, SNP genotyping, wide analysis, CpG site, DNA methylation, Medicine, Female, associations, Genotype, [SPI] Engineering Sciences [physics], Science, Single-nucleotide polymorphism, Locus (genetics), Human leukocyte antigen, Quantitative trait locus, Biology, Dna Methylation, Article, 03 medical and health sciences, bioconductor package, Bioconductor Package, expression, Inflammatory-bowel-disease, Humans, cancer, inflammatory-bowel-disease, Gene Expression Profiling, Celiac Disease, 030104 developmental biology, Gene Expression Regulation, CpG Islands, 030217 neurology & neurosurgery, Genome-Wide Association Study
Abstract

The Human Leucocyte Antigen (HLA) locus and other DNA sequence variants identified in Genome-Wide Association (GWA) studies explain around 50% of the heritability of celiac disease (CD). However, the pathogenesis of CD could be driven by other layers of genomic information independent from sequence variation, such as DNA methylation, and it is possible that allele-specific methylation explains part of the SNP associations. Since the DNA methylation landscape is expected to be different among cell types, we analyzed the methylome of the epithelial and immune cell populations of duodenal biopsies in CD patients and controls separately. We found a cell type-specific methylation signature that includes genes mapping to the HLA region, namely TAP1 and HLA-B. We also performed Immunochip SNP genotyping of the same samples and interrogated the expression of some of the affected genes. Our analysis revealed that the epithelial methylome is characterized by the loss of CpG island (CGI) boundaries, often associated to altered gene expression, and by the increased variability of the methylation across the samples. The overlap between differentially methylated positions (DMPs) and CD-associated SNPs or variants contributing to methylation quantitative trait loci (mQTLs) is minimal. In contrast, there is a notable enrichment of mQTLs among the most significant CD-associated SNPs. Our results support the notion that DNA methylation alterations constitute a genotype-independent event and confirm its role in the HLA region (apart from the well-known, DQ allele-specific effect). Finally, we find that a fraction of the CD-associated variants could exert its phenotypic effect through DNA methylation. The authors thank the technical and human support provided by SGIker of the UPV/EHU and the Genomics Platform at the CIC bioGUNE. We also thank Dr Florence Le Calvez-Kelm and Mr Geoffroy Durand from the Genetic Cancer Susceptibility group (IARC, Lyon) for their help with the HM450 beadchip assays. The work was funded by ISCIII Research Project Grants PI13/01201 and PI16/00258, cofunded by the European Union ERDF/ESF "A way to make Europe" co-financed by the Spanish Ministry of Economy and Competitiveness -http://www.mineco.gob.es/-and by the European Union ERDF/ESF "A way to make Europe" and project 2011/111034 from the Basque Department of Health -http://www.euskadi.eus/gobierno-vasco/departamento-salud/inicio/-to J.R.B. N.F.J. was supported by an IARC Postodctoral Fellowship (FP7 Marie Curie Actions-People-COFUND) and a Postdoctoral Fellowship from the Basque Department of Education -http://training.iarc.fr/en/fellowships/postdoc.php-.I.R.G.and A.J.M. are supported by Predoctoral Fellowship grants from the UPV/EHU and the Basque Department of Education -http://www.euskadi.eus/gobierno-vasco/departamento-educacion/-, respectively. S.E. was supported by the abovementioned IARC Postdoctoral Fellowship program. ACR is an Ikerbasque Research Fellow -http://www.ikerbasque.net/-.The funding bodies had no role in the design of the study and collection, analysis, and interpretation of data nor in writing the manuscript.

Published
2019

37. Roux-en-Y Gastric-Bypass and sleeve gastrectomy induces specific shifts of the gut microbiota without altering the metabolism of bile acids in the intestinal lumen

Author

Benoit Coffin, Dominique Rainteau, Jean-Baptiste Cavin, Anne-Charlotte Jarry, Henri Duboc, Harry Sokol, Lara Ribeiro-Parenti, Maude Le Gall, André Bado, Lydie Humbert, Caroline Chong Nguyen, Centre de recherche sur l'Inflammation (CRI (UMR_S_1149 / ERL_8252 / U1149)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC), Laboratoire des biomolécules (LBM UMR 7203), Centre National de la Recherche Scientifique (CNRS)-Sorbonne Université (SU)-Département de Chimie - ENS Paris, École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Chimie Moléculaire de Paris Centre (FR 2769), Institut de Chimie du CNRS (INC)-École normale supérieure - Paris (ENS Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI Paris), Université Paris sciences et lettres (PSL)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Sorbonne Université (SU), Center for Computational Imaging and Simulation Technologies in Biomedicine (CISTIB), Universitat Pompeu Fabra [Barcelona] (UPF), Gastroenterology Unit, Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Gastroentérologie et nutrition [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), MICrobiologie de l'ALImentation au Service de la Santé (MICALIS), Institut National de la Recherche Agronomique (INRA)-AgroParisTech, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Chimie Moléculaire de Paris Centre (FR 2769), Université Pierre et Marie Curie - Paris 6 (UPMC)-ESPCI ParisTech-Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL (ENSCP)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris)-Université Pierre et Marie Curie - Paris 6 (UPMC)-ESPCI ParisTech-Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL (ENSCP)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS Paris)-Département de Chimie - ENS Paris, École normale supérieure - Paris (ENS Paris)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Universitat Pompeu Fabra [Barcelona], Hopital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], LE GALL, Maude, École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Institut de Chimie du CNRS (INC)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Paris (ENS-PSL), Université Paris sciences et lettres (PSL)-Institut de Chimie du CNRS (INC)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-Département de Chimie - ENS Paris, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Recherche Saint-Antoine (CRSA), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)

Subjects
obesity, Sleeve gastrectomy, medicine.medical_specialty, [SDV.MHEP.CHI] Life Sciences [q-bio]/Human health and pathology/Surgery, bariatric surgery, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, Gastric Bypass, Medicine (miscellaneous), Lumen (anatomy), 030209 endocrinology & metabolism, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, Gut flora, digestive system, Bile Acids and Salts, 03 medical and health sciences, Cecum, 0302 clinical medicine, Gastrectomy, Internal medicine, medicine, Animals, 030212 general & internal medicine, Rats, Wistar, [SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitology, Nutrition and Dietetics, biology, Chemistry, Stomach, dysbiosis, Metabolism, medicine.disease, biology.organism_classification, Gastrointestinal Microbiome, Obesity, Morbid, Rats, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, medicine.anatomical_structure, Endocrinology, Duodenum, Dysbiosis, weight-loss
Abstract

International audience; Some shifts in the gut microbiota composition and its metabolic fingerprints have been associated to Sleeve gastrectomy (SG) and Roux-en-Y Gastric Bypass (RYGB). So far, plasma bile acids have been associated with post-operative glucose improvement and weight loss, but nothing is known about their metabolism in the gut lumen. As bile acids are physiologically transformed by the microbiota into various species, the aim of this work was to study how SG and RYGB-associated dysbiosis impact the bioconversion of bile acids in the intestinal lumen. Comparing SHAM (n = 9) with our validated rat models of SG (n = 5) and RYGB (n = 6), we quantified luminal bile acids along the gut and found that the metabolic transformation of bile acids (deconjugation, dehydroxylation, and epimerization) is not different from the duodenum to the colon. However, in the cecum where the biotransformation mainly takes place, we observed deep alterations of the microbiota composition, which were specific of each type of surgery. In conclusion, despite specific dysbiosis after surgery, the bile acids metabolism in the gut lumen is highly preserved, suggesting that a resilience of the gut microbiota occurs after these procedures.

Published
2018

40. Update of the statements on biology and clinical impact of occult hepatitis B virus infection

Author

Ding-Shinn Chen, Thomas Berg, Giovanni Battista Gaeta, Alfredo Marzano, Luca G. Guidotti, Vito Di Marco, Massimo Levrero, Antonio Craxì, Anna Kramvis, Anna S. Lok, Nicola Coppola, Giovanni Raimondo, Jean-Michel Pawlotsky, Teresa Pollicino, Dieter Glebe, Man-Fung Yuen, Didier Samuel, Maurizia Rossana Brunetto, Antonio Bertoletti, Daniele Prati, Massimo Puoti, Thomas I. Michalak, Jake Liang, Vincent Soriano, Pietro Lampertico, Raffaele Bruno, Fabien Zoulim, Christian Trepo, Chengyao Li, Camille Sureau, Stephen Locarnini, Giovanni Squadrito, C. Ferrari, Markus Cornberg, Jean-Pierre Allain, Maura Dandri, Department of Internal Medicine, University of Messina, Victorian Infectious Diseases Reference Laboratory, Center for Life Nanoscience/IIT@Sapienza [Rome, Italy] (CLNS@SAPIENZA Roma), Instituto Italiano di Tecnologia [Rome, Italy], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Division of Gastroenterology, University of Michigan [Ann Arbor], University of Michigan System-University of Michigan System, Division of Transfusion Medicine, University of Cambridge [UK] (CAM), Department of Medical Biochemistry, Uni, Institute of Infectious and Tropical Diseases, Università degli Studi di Pavia, European XFEL GmbH (XFEL), European XFEL GmbH, Department of Gastroenterology, Hepatology and Endocrinology (MHH), Hannover Medical School [Hannover] (MHH), Università degli studi di Palermo - University of Palermo, Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), Infectious Diseases Dept, University of Naples Federico II, I Gastroenterology Unit, Department of Medicine, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Case Western Reserve University [Cleveland], Centre National de Référence Virus des hépatites B, C et Delta, Institut National de la Transfusion Sanguine [Paris] (INTS)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Transfusion Medicine and Hematology, Alessandro Manzoni Hospital, Department of infectious Diseases, Hôpital Paul Brousse, Institut National de la Transfusion Sanguine [Paris] (INTS), Immunité muqueuse et vaccination, Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-IFR50-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Raimondo, G, Locarnini, S, Pollicino, T, Levrero, M, Zoulim, F, Lok, A, Allain, J, Berg, T, Bertoletti, A, Brunetto, M, Bruno, R, Chen, D, Coppola, N, Cornberg, M, Craxi, A, Dandri, M, Di Marco, V, Ferrari, C, Gaeta, G, Glebe, D, Guidotti, L, Kramvis, A, Lampertico, P, Li, C, Liang, J, Marzano, A, Michalak, T, Pawlotsky, J, Prati, D, Puoti, M, Samuel, D, Soriano, V, Squadrito, G, Sureau, C, Trepo, C, Yuen, M, Raimondo G., Locarnini S., Pollicino T., Levrero M., Zoulim F., Lok A.S., Allain J.-P., Berg T., Bertoletti A., Brunetto M.R., Bruno R., Chen D.-S., Coppola N., Cornberg M., Craxi A., Dandri M., Di Marco V., Ferrari C., Gaeta G.B., Glebe D., Guidotti L.G., Kramvis A., Lampertico P., Li C., Liang J., Marzano A., Michalak T.I., Pawlotsky J.-M., Prati D., Puoti M., Samuel D., Soriano V., Squadrito G., Sureau C., Trepo C., Yuen M.-F., Raimondo, G., Locarnini, S., Pollicino, T., Levrero, M., Zoulim, F., Lok, A. S., Allain, J. -P., Berg, T., Bertoletti, A., Brunetto, M. R., Bruno, R., Chen, D. -S., Coppola, N., Cornberg, M., Craxi, A., Dandri, M., Di Marco, V., Ferrari, C., Gaeta, G. B., Glebe, D., Guidotti, L. G., Kramvis, A., Lampertico, P., Li, C., Liang, J., Marzano, A., Michalak, T. I., Pawlotsky, J. -M., Prati, D., Puoti, M., Samuel, D., Soriano, V., Squadrito, G., Sureau, C., Trepo, C., and Yuen, M. -F.

Subjects
0301 basic medicine, Occult HBV infection, Hepatitis B virus, medicine.medical_specialty, Carcinoma, Hepatocellular, Hepatocellular carcinoma, Hbv reactivation, MEDLINE, HBV reactivation, OBI, medicine.disease_cause, 03 medical and health sciences, 0302 clinical medicine, HBV S variant, Risk Factors, medicine, Humans, Hepatitis B Antibodies, Intensive care medicine, ComputingMilieux_MISCELLANEOUS, Hepatitis B Surface Antigens, Hepatology, HBV cccDNA, Liver Neoplasms, virus diseases, HBV S variants, HBV transmission, Hepatitis B, medicine.disease, Occult, digestive system diseases, 3. Good health, 030104 developmental biology, Liver, DNA, Viral, 030211 gastroenterology & hepatology, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

In October 2018 a large number of international experts with complementary expertise came together in Taormina to participate in a workshop on occult hepatitis B virus infection (OBI). The objectives of the workshop were to review the existing knowledge on OBI, to identify issues that require further investigation, to highlight both existing controversies and newly emerging perspectives, and ultimately to update the statements previously agreed in 2008. This paper represents the output from the workshop.

Published
2019

41. A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices

Author

Federico Ravaioli, M. Rosselli, Giuseppe Mazzella, Mirella Fraquelli, Antonio Colecchia, Corina Rusu, Nathalie Ganne-Carrié, Giovanni Marasco, Paul Calès, Davide Festi, Horia Stefanescu, Victor de Ledinghen, Pietro Andreone, Stefanescu H., Marasco G., Cales P., Fraquelli M., Rosselli M., Ganne-Carrie N., de Ledinghen V., Ravaioli F., Colecchia A., Rusu C., Andreone P., Mazzella G., Festi D., Regional Institute of Gastroenterology and Hepatology [Cluj-Napoca], Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), II Gastroenterology Unit, Department of Medicine, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Physiopathologie du cancer du foie, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Bordeaux Segalen - Bordeaux 2, and Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO)

Subjects
Male, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Baveno VI criteria, liver stiffness measurement, portal hypertension, spleen stiffness measurement, Chronic liver disease, Esophageal and Gastric Varices, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Liver stiffness, Predictive Value of Tests, Internal medicine, medicine, Humans, Prospective Studies, ComputingMilieux_MISCELLANEOUS, Aged, Hepatology, medicine.diagnostic_test, business.industry, Platelet Count, Liver Diseases, Reproducibility of Results, Middle Aged, medicine.disease, 3. Good health, Endoscopy, Logistic Models, 030220 oncology & carcinogenesis, Multivariate Analysis, Portal hypertension, Elasticity Imaging Techniques, 030211 gastroenterology & hepatology, Female, business, Varices, Spleen
Abstract

Background & Aims Several non-invasive tests (NITs) have been developed to diagnose oesophageal varices (EV), including the recent Baveno VI criteria to rule out high-risk varices (HRV). Spleen stiffness measurement (SSM) with the standard FibroScan (R) (SSM@50Hz) has been evaluated. However, the EV grading could be underestimated because of a ceiling threshold (75 kPa) of the SSM@50Hz. The aims were to evaluate SSM by a novel spleen-dedicated FibroScan (R) (SSM@100Hz) for EV diagnosis compared with SSM@50Hz, other validated NITs and Baveno VI criteria. Methods This prospective multicentre study consecutively enrolled patients with chronic liver disease; blood data, endoscopy, liver stiffness measurement (LSM), SSM@50Hz and SSM@100Hz were collected. Results Two hundred and sixty patients met inclusion criteria. SSM@100Hz success rate was significantly higher than that of SSM@50Hz (92.5% vs 76.0%, P < .001). SSM@100Hz accuracy for the presence of EV (AUC = 0.728) and HRV (AUC = 0.756) was higher than in other NITs. SSM@100Hz AUC for large EV (0.782) was higher than SSM@50Hz (0.720, P = .027). AUC for HRV with SSM@100Hz (0.780) was higher than with LSM (0.615, P < .001). The spared endoscopy rate of Baveno VI criteria (8.1%) was significantly increased by the combination to SSM@50Hz (26.5%) or SSM@100Hz (38.9%, P < .001 vs others). The missed HRV rate was, respectively, 0% and 4.7% for combinations. Conclusions SSM@100Hz is a new performant non-invasive marker for EV and HRV providing a higher accuracy than SSM@50Hz and other NITs. The combination of Baveno VI criteria and SSM@100Hz significantly increased the spared endoscopy rate compared to Baveno VI criteria alone or combined with SSM@50Hz. Clinical trial number: NCT02180113.

Published
2019

42. The experience of inflammatory bowel disease patients with healthcare A survey with the IEXPAC instrument

Author

Xavier Cortés, Luis Cea-Calvo, Ester Navarro-Correal, Domingo Orozco-Beltrán, Mariana F García-Sepulcre, Ignacio Marín-Jiménez, Nadia Soto, María José Galindo, Javier de Toro, R Saldaña, Francesc Casellas, Berta Juliá, Institut Català de la Salut, [Marín-Jiménez I] IBD Unit, Gastroenterology Department Clinical Research Institute Gregorio Marañón (IiSGM), Madrid, Spain. [Casellas F, Navarro-Correal E] Unitat d’Atenció Crohn-Colitis, Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Cortés X] Gastroenterology Unit, Sagunto Hospital, Valencia, Spain. [García-Sepulcre MF] Elche University Hospital, Elche, Spain. [Juliá B, Cea-Calvo L] Medical Affairs Department, Merck Sharp & Dohme Spain, Madrid, Spain., and Vall d'Hebron Barcelona Hospital Campus

Subjects
medicine.medical_specialty, Cross-sectional study, Intestins - Inflamació - Aspectes psicològics, MEDLINE, Inflammatory bowel disease, enfermedades del sistema digestivo::enfermedades gastrointestinales::gastroenteritis::enfermedad inflamatoria intestinal [ENFERMEDADES], conducta y mecanismos de la conducta::actitud::actitud ante la salud::cumplimiento y adherencia al tratamiento::satisfacción del paciente [PSIQUIATRÍA Y PSICOLOGÍA], Other subheadings::/statistics & numerical data [Other subheadings], 03 medical and health sciences, 0302 clinical medicine, Malalties cròniques - Aspectes psicològics, inflammatory bowel disease, Other subheadings::/psychology [Other subheadings], Internal medicine, Patient experience, Health care, Medicine, Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic Disease [DISEASES], Otros calificadores::/estadística & datos numéricos [Otros calificadores], 030212 general & internal medicine, IEXPAC instrument, Digestive System Diseases::Gastrointestinal Diseases::Gastroenteritis::Inflammatory Bowel Diseases [DISEASES], business.industry, afecciones patológicas, signos y síntomas::procesos patológicos::atributos de la enfermedad::enfermedad crónica [ENFERMEDADES], healthcare, Otros calificadores::/psicología [Otros calificadores], Mean age, General Medicine, Pacients - Satisfacció - Estadístiques, Behavior and Behavior Mechanisms::Attitude::Attitude to Health::Treatment Adherence and Compliance::Patient Satisfaction [PSYCHIATRY AND PSYCHOLOGY], medicine.disease, Chronic disease, 030220 oncology & carcinogenesis, business
Abstract

Inflammatory bowel disease; Patients experience; Chronic disease Malaltia intestinal inflamatòria; Experiència dels pacients; Malalties cròniques Enfermedad intestinal inflamatoria; Experiencia de los pacientes; Enfermedades crónicas To assess inflammatory bowel disease (IBD) patients' experience of chronic illness care and the relationship with demographic and healthcare-related characteristics.This cross-sectional survey used the Instrument to Evaluate the EXperience of PAtients with Chronic diseases (IEXPAC) questionnaire to identify parameters associated with a better healthcare experience for IBD patients. IEXPAC questionnaire responses are grouped into 3 factors - productive interactions, new relational model, and patient self-management, scoring from 0 (worst) to 10 (best experience). Scores were analyzed by bivariate comparisons and multiple linear regression models.Surveys were returned by 341 of 575 patients (59.3%, mean age 46.8 (12.9) years, 48.2% women). Mean (SD) IEXPAC score was 5.9 (2.0); scores were higher for the productive interactions (7.7) and patient self-management factors (6.7) and much lower for the new relational model factor (2.2). Follow-up by a nurse, being seen by the same physician, and being treated with a lower number of medicines were associated with higher (better) overall patient experience score, and higher productive interactions and self-management factor scores. A higher productive interactions score was also associated with patients receiving medication subcutaneously or intravenously. Higher new relational model scores were associated with follow-up by a nurse, affiliation to a patients' association, receiving help from others for healthcare, a lower number of medicines and a higher educational level.In patients with IBD, a better overall patient experience was associated with follow-up by a nurse, being seen by the same physician, and being treated with a lower number of medicines.

Published
2019

43. Outcomes 7 Years After Infliximab Withdrawal for Patients With Crohn’s Disease in Sustained Remission

Author

Reenaers, Catherine, Mary, Jean-Yves, Nachury, Maria, Bouhnik, Yoram, Laharie, David, Allez, Matthieu, Fumery, Mathurin, Amiot, Aurélien, Savoye, Guillaume, Altwegg, Romain, Devos, Martine, Malamut, Georgia, Bourreille, Arnaud, Flourie, Bernard, Marteau, Philippe, Vuitton, Lucine, Coffin, Benoit, Viennot, Stéphanie, Lambert, Jérôme, Colombel, Jean-Frédéric, Louis, Edouard, Getaid, Groupe d'Etude Thérapeutique Des Affections, Université de Liège, Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité (CRESS (U1153 / UMR_A_1125 / UMR_S_1153)), Institut National de la Recherche Agronomique (INRA)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Biostatistique et épidemiologie clinique, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de gastro-entérologie et assistance nutritive, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'Hépato-Gastro-Entérologie, CHU Bordeaux [Bordeaux]-Hôpital Saint-André, Infection à helicobacter, inflammation et cancer, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), CHU Amiens-Picardie, Service d'hépato-gastro-entérologie [APHP Henri Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'Hépato-Gastroentérologie [CHU Rouen], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Nutrition, inflammation et dysfonctionnement de l'axe intestin-cerveau (ADEN), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institute for Research and Innovation in Biomedicine (IRIB), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Hépato-gastro-entérologie, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Universiteit Gent = Ghent University [Belgium] (UGENT), Service de gastroenterologie [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Neuropathies du système nerveux entérique et pathologies digestives, implication des cellules gliales entériques, Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hepato-Gastroenterology, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), gastroenterology, Lariboisière hospital, Hôpital Lariboisière-Fernand-Widal [APHP], Service de Gastro-Entérologie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Gastroenterology Unit, Hôpital Louis Mourier - AP-HP [Colombes], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Côte de Nacre [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Icahn Medical Institute-Mount Sinai School of Medicine, Department of Gene and Cell Medicine and Institute for Immunology, Groupe d’Étude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID), Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de la Recherche Agronomique (INRA), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Hôpital Charles Nicolle [Rouen]-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Faculty of Medicine and Health Science, University of Ghent, Ghent, Belgium, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon, Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Centre hospitalier universitaire d'Amiens (CHU Amiens-Picardie), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'Hépato-Gastroentérologie [Rouen], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hôpital Lariboisière, AP-HP, Paris, Service d'Hépato-gastro-entérologie [Hôpital Jean Minjoz], Hôpital Jean Minjoz, Hopital Louis Mourier - AP-HP [Colombes], GETAID, and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)

Subjects
musculoskeletal diseases, Adult, Male, medicine.medical_specialty, Disease, 03 medical and health sciences, 0302 clinical medicine, Maintenance therapy, Belgium, Crohn Disease, Gastrointestinal Agents, Interquartile range, Recurrence, Internal medicine, medicine, Humans, Prospective Studies, ComputingMilieux_MISCELLANEOUS, Crohn's disease, Hepatology, biology, business.industry, C-reactive protein, Gastroenterology, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, medicine.disease, Infliximab, 3. Good health, Surgery, Discontinuation, Treatment Outcome, 030220 oncology & carcinogenesis, Cohort, biology.protein, 030211 gastroenterology & hepatology, Female, France, business, medicine.drug, Follow-Up Studies
Abstract

Background & Aims Little is known about long-term outcomes of patients with Crohn's disease (CD) after infliximab withdrawal. We aimed to describe the long-term outcomes of patients with CD in clinical remission after infliximab treatment was withdrawn. Methods We performed a retrospective analysis of data from the 115 patients included in the infliximab discontinuation in patients with CD in stable remission on combined therapy with antimetabolites (STORI) study, performed at 20 centers in France and Belgium from March 2006 through December 2009. The STORI cohort was a prospective analysis of risk and factors associated with relapse following withdrawal of maintenance therapy with infliximab, maintained on antimetabolites, while in clinical remission. We collected data from the end of the study until the last available follow-up examination on patient surgeries, new complex perianal lesions (indicating major complications), and need for and outcomes of restarting therapy with infliximab or another biologic agent. The de-escalation strategy was considered to have failed when a major complication or infliximab restart failure occurred. Results Of the 115 patients initially included, data from 102 patients (from 19 of the 20 study centers) were included in the final analysis. The median follow-up time was 7 years. Twenty-one percent of the patients did not restart treatment with infliximab or another biologic agent and did not have a major complication 7 years after infliximab withdrawal (95% CI, 13.1–30.3). Among patients who restarted infliximab, treatment failed for 30.1% 6 years after restarting (95% CI, 18.5–42.5). Overall, at 7 years after stopping infliximab therapy, major complications occurred in 18.5% of patients (95% CI, 10.2–26.8) whereas 70.2% of patients had no failure of the de-escalation strategy (95% CI, 60.2–80.1). Factors independently associated with major complications were upper-gastrointestinal location of disease, white blood cell count ≥ 5.0 × 109/L, and hemoglobin level ≤12.5 g/dL at the time of infliximab withdrawal. Patients with at least 2 of these factors had a more than 40% risk of major complication in the 7 years following infliximab withdrawal. Conclusions In a long-term follow-up of the STORI cohort (7 years) one fifth of the patients did not restart infliximab or another biologic agent and did not develop major complications. Seventy percent of patients had no failure of the de-escalation strategy (no major complication and no failure of infliximab restart).

Published
2018

44. Involvement of opioid system, TRPM8, and ASIC receptors in antinociceptive effect of Arrabidaea brachypoda (DC) bureau

Author

Larissa Lucena Périco, Lucia Regina Machado da Rocha, Adair R.S. Santos, Raquel de Cássia dos Santos, Jean-Luc Wolfender, Cláudia Quintino da Rocha, Vinícius Peixoto Rodrigues, Rie Ohara, Catarine Massucato Nishijima, Clélia Akiko Hiruma-Lima, Emerson Ferreira Queiroz, Wagner Vilegas, Universidade Estadual Paulista (Unesp), Federal University of Maranhão, Clinical Pharmacology and Gastroenterology Unit (USF), University of Lausanne, and Universidade Federal de Santa Catarina (UFSC)

Subjects
Male, 0301 basic medicine, Medicinal/chemistry, Antinociceptive effect, Pharmacology, Plant Roots, Plant Extracts/chemistry/isolation & purification/pharmacology/therapeutic use, lcsh:Chemistry, Mice, Transient receptor potential channel, 0302 clinical medicine, Pain/drug therapy/metabolism, pain, Acid Sensing Ion Channels/metabolism, Receptor, lcsh:QH301-705.5, Spectroscopy, Opioidergic, Analgesics, ddc:615, Chemistry, General Medicine, Plants, Computer Science Applications, Nociception, Arrabidaea brachypoda (DC) Bureau, Bignoniaceae, antinociceptive effect, medicine.symptom, Locomotion, Bignoniaceae/chemistry, TRPV1, TRPM Cation Channels, Pain, Article, Catalysis, Inorganic Chemistry, 03 medical and health sciences, Glutamatergic, Locomotion/drug effects, medicine, TRPM8, Animals, Physical and Theoretical Chemistry, Molecular Biology, Plant Roots/chemistry, Plants, Medicinal, Plant Extracts, Organic Chemistry, TRPM Cation Channels/metabolism, Acid Sensing Ion Channels, Analgesics/chemistry/isolation & purification/pharmacology/therapeutic use, 030104 developmental biology, Mechanism of action, lcsh:Biology (General), lcsh:QD1-999, 030217 neurology & neurosurgery, Phytotherapy, Arrabidaea brachypoda (dc) bureau
Abstract

Made available in DSpace on 2018-12-11T17:34:47Z (GMT). No. of bitstreams: 0 Previous issue date: 2017-11-02 Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) Arrabidaea brachypoda (DC) Bureau is a medicinal plant found in Brazil. Known as “ció-una”, it is popularly used as a natural therapeutic agent against pain and inflammation. This study evaluated the chemical composition and antinociceptive activity of the dichloromethane fraction from the roots of A. brachypoda (DEAB) and its mechanism of action. The chemical composition was characterized by high-performance liquid chromatography, and this fraction is composed only of dimeric flavonoids. The antinociceptive effect was evaluated in formalin and hot plate tests after oral administration (10-100 mg/kg) in male Swiss mice. We also investigated the involvement of TRPV1 (transient receptor potential vanilloid 1), TRPA1 (transient receptor potential ankyrin 1), TRPM8 (transient receptor potential melastatin 8), and ASIC (acid-sensing ion channel), as well as the opioidergic, glutamatergic, and supraspinal pathways. Moreover, the nociceptive response was reduced (30 mg/kg) in the early and late phase of the formalin test. DEAB activity appears to involve the opioid system, TRPM8, and ASIC receptors, clearly showing that the DEAB alleviates acute pain in mice and suggesting the involvement of the TRPM8 and ASIC receptors and the opioid system in acute pain relief. São Paulo State University (UNESP) Biosciences Institute Department of Physiology Department of Chemistry Federal University of Maranhão, Av. dos Portugueses, 1966â-Bacanga Clinical Pharmacology and Gastroenterology Unit (USF) School of Pharmaceutical Sciences EPGL University of Geneva University of Lausanne, CMU-Rue Michel-Servet 1 Federal University of Santa Catarina Laboratory of Neurobiology of Pain and Inflammation Department of Physiological Sciences Center of Biological Sciences, Trindade Biosciences Institute São Paulo State University (UNESP) São Paulo State University (UNESP) Biosciences Institute Department of Physiology Biosciences Institute São Paulo State University (UNESP) FAPESP: 2009/52237-9 CNPq: 305570/2012-9

Published
2017

45. Development and validation of the Nancy histological index for UC

Author

Stefan Schreiber, Laurent Peyrin-Biroulet, Guillaume Cadiot, Virginie Cahn, Simon Travis, Silvio Danese, Aude Marchal-Bressenot, Walter Reinisch, Marie-Danièle Diebold, Claire Bastien, Julia Salleron, Camille Boulagnon-Rombi, Service de Pathologie [CHU Reims], Centre Hospitalier Universitaire de Reims (CHU Reims), Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Département de biostatistiques [ICL Alexis Vautrin], Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), UNICANCER-UNICANCER, Service de Pathologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Département de Pathologie [Centre Hospitalier Sud Francilien], Centre Hospitalier Sud Francilien, CH Evry-Corbeil-CH Evry-Corbeil, Service d'hépato-gastroentérologie (CHU Reims), Gastroenterology [Istituto Clinico Humanitas], Istituto Clinico Humanitas [Milan] (IRCCS Milan), Humanitas University [Milan] (Hunimed)-Humanitas University [Milan] (Hunimed), University Medical Center of Schleswig–Holstein = Universitätsklinikum Schleswig-Holstein (UKSH), Kiel University, Translational Gastroenterology Unit [Oxford University Hospitals], Oxford University Hospitals NHS Trust, University of Oxford [Oxford]-University of Oxford [Oxford], Service d'Hépato-gastro-entérologie [CHRU Nancy], Marchal-Bressenot, A, Salleron, J, Boulagnon-Rombi, C, Bastien, C, Cahn, V, Cadiot, G, Diebold, Md, Danese, S, Reinisch, W, Schreiber, S, Travis, S, and Peyrin-Biroulet, L

Subjects
medicine.medical_specialty, Pathology, Coefficient of determination, Index (economics), Colon, Intraclass correlation, Biopsy, [SDV]Life Sciences [q-bio], Severity of Illness Index, Correlation, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Active disease, Linear regression, Severity of illness, medicine, Humans, Ulcerative Colitis, IBD CLINICAL, Observer Variation, medicine.diagnostic_test, business.industry, Gastroenterology, Reproducibility of Results, HISTOPATHOLOGY, PostScript, 030220 oncology & carcinogenesis, Linear Models, Colitis, Ulcerative, 030211 gastroenterology & hepatology, Mucosal Pathology, business, Algorithms
Abstract

Objective We developed a validated index for assessing histological disease activity in UC and established its responsiveness. Methods Two hundred biopsies were scored. The outcome was the Global Visual Evaluation (GVE). Eight histological features were tested. The Nancy index was developed by multiple linear regression and bootstrap process to create an index that best matched the GVE. Goodness of fit was assessed by the adjusted R squared (adjusted R-2). The second step was the validation of the index: 100 biopsies were scored for the Nancy index by three pathologists from different centres. Inter-reader reliability was evaluated for each reader. The relationship between the change of the Nancy index and the Geboes index was assessed to assess the responsiveness. Results After backward selection with bootstrap validation, 3/8 items were selected: ulceration (adjusted R-2=0.55), acute inflammatory infiltrate (adjusted R-2=0.88) and chronic inflammatory infiltrate (adjusted R-2=0.79). The Nancy index is defined by a 5-level classification ranging from grade 0 (absence of significant histological disease activity) to grade 4 (severely active disease). The intraclass correlation coefficient (ICC) for the intrareader reliability was 0.88 (95% CI 0.82 to 0.92) and the index had good interreader reliability (ICC=0.86 (0.81 to 0.99)). The correlation between the Nancy index and the Geboes score or the GVE was very good. The index had a good responsiveness with a high correlation between changes in the Geboes score and changes in the Nancy index (0.910 (0.813 to 0.955)). Conclusions A three descriptor histological index has been validated for use in clinical practice and clinical trials.

Published
2016

46. Fecal Gluten Peptides Reveal Limitations of Serological Tests and Food Questionnaires for Monitoring Gluten-Free Diet in Celiac Disease Patients

Author

Miguel Bolonio, Gemma Castillejo, Antonio Millán, Victoria Alejandra Jiménez-García, Luis Fernández-Salazar, Alfonso Rodríguez-Herrera, José Carlos Salazar, Carmen Ribes-Koninckx, Eduardo Arranz, Luis Vaquero, Carolina Sousa, Alba Muñoz-Suano, Mercè Rosinach, Justo Valverde, M.A. Montes-Cano, Santiago Vivas, Blanca Fambuena, Ana María Vegas, Luis Ortigosa, Verónica Segura, Alejandro Nuñez, Jorge Marinich, Francesc Martínez Cerezo, Beatriz Espín, Carlos Sierra, Oreste Lo Iacono, Francisco Leon, José Ramón Alberto, César Guajardo, Ángel Caunedo, Francisco José Girón, José Antonio Garrote, Laura Crespo, Ana Galera, Angel Cebolla, Fernando Fernández-Bañares, Maria Esteve, Manuel Romero-Gómez, J M Marugán-Miguelsanz, Isabel Comino, European Commission, Corporación Tecnológica de Andalucía, Ministerio de Ciencia e Innovación (España), Universidad de Sevilla. Departamento de Microbiología y Parasitología, [Comino,I, Segura,V, Sousa,C] Department of Microbiology and Parasitology, Faculty of Pharmacy, University of Seville, Seville, Spain. [Fernández-Bañares,F, Esteve,M, Rosinach,M] Department of Gastroenterology, Hospital Universitari Mutua Terrassa, and CIBERehd, Terrassa, Barcelona, Spain. [Ortigosa,L, Guajardo,C, Alberto, JR] Pediatric Gastroenterology, Hospital Universitario Nuestra Señora de La Candelaria, Tenerife, Spain. [Castillejo,G, Martínez Cerezo,F] Pediatric Gastroenterology, Hospital Universitari de Sant Joan de Reus, IISPV, URV, Reus, Spain. [Fambuena,B, Romero-Gómez,M, Millán,A] Unit for the Clinical Management of Digestive Diseases and CIBERehd and Gastroenterology and Nutrition Unit, Hospital Universitario Virgen de Valme, Seville, Spain. [Ribes-Koninckx,C, Bolonio,M] Pediatric Gastroenterology, Hepatology and Nutrition Unit, Hospital Universitario y Politécnico La Fe, Celiac Disease and Digestive Inmunopatology Unit, Instituto de Investigación Sanitaria La Fe, Valencia, Spain. [Sierra,C, Girón,.FJ] Pediatric Gastroenterology and Nutrition Unit, Hospital Materno-Infantil, Malaga, Spain. [Rodríguez-Herrera,A, Galera,A, Valverde,J] Gastroenterology and Nutrition Unit, Instituto Hispalense de Pediatría, Seville, Spain. [Salazar,JC, Espín,B] Servicio de Gastroenterología Pediátrica, Hospital Universitario Virgen del Rocío, Seville, Spain. [Caunedo,A, Jiménez-García,VA] Hospital Universitario Virgen Macarena, Seville, Spain. [Marugán-MiguelSanz,JM, Fernández-Salazar,L, Arranz,E] Mucosal Immunology Laboratory, Instituto de Biología y Genética Molecular (IBGM), University of Valladolid, CSIC and Gastroenterology Unit, Hospital Clínico Universitario de Valladolid, Valladolid, Spain. [Garrote,JA, Vegas, AM, Crespo,L] Clinical Analysis and Pediatrics, Hospital Universitario Río Hortega, Valladolid, Spain. [Vivas,S, Nuñez,A, Vaquero,LServicio de Aparato Digestivo, Hospital Universitario de Leon, Leon, Spain. [Lo Iacono,O] Sección de Aparato Digestivo, Hospital del Tajo, Madrid, Spain. [Montes-Cano,MA] Servicio de Inmunología, CIBER de Epidemiología y Salud Pública, Hospital Universitario Virgen del Rocío/IBiS/CSIC/Universidad de Sevilla, Seville, Spain. [León,F] Celimmune, Bethesda, Maryland, USA. [Marinich,J, Muñoz-Suano,A, Cebolla,A] Biomedal SL, Seville, Spain., and Th is work was supported by grants from Ministerio de Ciencia e Innovación and FEDER funds (DELIAC, IPT-2011-0952-900000), and Corporación Tecnológica de Andalucía (SINGLUCHECK, 1737/0118).

Subjects
Proteínas de unión al GTP, Male, Pathology, Enfermedad celíaca, Tissue transglutaminase, Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Malabsorption Syndromes::Celiac Disease [Medical Subject Headings], Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Immunologic Techniques::Immunohistochemistry::Immunoenzyme Techniques::Enzyme-Linked Immunosorbent Assay [Medical Subject Headings], Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Plant Proteins::Seed Storage Proteins::Prolamins::Glutens::Gliadin [Medical Subject Headings], Gastroenterology, Gliadin, Serology, Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], Feces, 0302 clinical medicine, Surveys and Questionnaires, Estudios prospectivos, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Carrier Proteins::GTP-Binding Proteins [Medical Subject Headings], Ingestion, Ensayo de inmunoadsorción enzimática, 030212 general & internal medicine, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [Medical Subject Headings], Prospective Studies, Young adult, Prospective cohort study, Masculino, Child, chemistry.chemical_classification, biology, Health Care::Health Care Quality, Access, and Evaluation::Delivery of Health Care::Attitude to Health::Patient Acceptance of Health Care::Patient Compliance [Medical Subject Headings], Gliadina, Age Factors, Diet Records, Humanos, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Plant Proteins::Seed Storage Proteins::Prolamins::Glutens [Medical Subject Headings], Encuestas y cuestionarios, Child, Preschool, Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Health Care Evaluation Mechanisms::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Prospective Studies [Medical Subject Headings], 030211 gastroenterology & hepatology, Female, Inmunoglobulina A, medicine.medical_specialty, Adolescent, Glutens, Check Tags::Male [Medical Subject Headings], Enzyme-Linked Immunosorbent Assay, Antibodies, 03 medical and health sciences, Diet, Gluten-Free, Young Adult, GTP-Binding Proteins, Internal medicine, medicine, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Peptides [Medical Subject Headings], Humans, Protein Glutamine gamma Glutamyltransferase 2, Serologic Tests, Cooperación del paciente, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Immunoglobulin Isotypes::Immunoglobulin A [Medical Subject Headings], Autoantibodies, Transglutaminases, Hepatology, business.industry, Case-control study, Péptidos, nutritional and metabolic diseases, Infant, Dieta sin gluten, Glútenes, Colon/Small Bowel, Gluten, Chemicals and Drugs::Enzymes and Coenzymes::Enzymes::Transferases::Acyltransferases::Aminoacyltransferases::Transglutaminases [Medical Subject Headings], Transglutaminasas, digestive system diseases, Immunoglobulin A, Celiac Disease, chemistry, Case-Control Studies, biology.protein, Patient Compliance, Gluten free, Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet::Diet, Gluten-Free [Medical Subject Headings], business, 3206 Ciencias de la Nutrición
Abstract

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License.-- et al., [Objectives]: Treatment for celiac disease (CD) is a lifelong strict gluten-free diet (GFD). Patients should be followed-up with dietary interviews and serology as CD markers to ensure adherence to the diet. However, none of these methods offer an accurate measure of dietary compliance. Our aim was to evaluate the measurement of gluten immunogenic peptides (GIP) in stools as a marker of GFD adherence in CD patients and compare it with traditional methods of GFD monitoring. [Methods]: We performed a prospective, nonrandomized, multicenter study including 188 CD patients on GFD and 84 healthy controls. Subjects were given a dietary questionnaire and fecal GIP quantified by enzyme-linked immunosorbent assay (ELISA). Serological anti-tissue transglutaminase (anti-tTG) IgA and anti-deamidated gliadin peptide (anti-DGP) IgA antibodies were measured simultaneously. [Results]: Of the 188 celiac patients, 56 (29.8%) had detectable GIP levels in stools. There was significant association between age and GIP in stools that revealed increasing dietary transgressions with advancing age (39.2% in subjects ≥13 years old) and with gender in certain age groups (60% in men ≥13 years old). No association was found between fecal GIP and dietary questionnaire or anti-tTG antibodies. However, association was detected between GIP and anti-DGP antibodies, although 46 of the 53 GIP stool-positive patients were negative for anti-DGP. [Conclusions]: Detection of gluten peptides in stools reveals limitations of traditional methods for monitoring GFD in celiac patients. The GIP ELISA enables direct and quantitative assessment of gluten exposure early after ingestion and could aid in the diagnosis and clinical management of nonresponsive CD and refractory CD. Trial registration number NCT02711397., This work was supported by grants from Ministerio de Ciencia e Innovación and FEDER funds (DELIAC, IPT-2011-0952-900000), and Corporación Tecnológica de Andalucía (SINGLUCHECK, 1737/0118).

Published
2016

47. Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study

Author

Qian Ding, Mark Lynam, Andreas Sturm, Alessandro Armuzzi, Shaji Sebastian, Gert Van Assche, Nuria Lara, Sumesh Kachroo, Christopher M. Black, Laurent Peyrin-Biroulet, Sonia Rojas-Farreras, Daniel R. Gaya, Tao Fan, Gerassimos J. Mantzaris, Bern Bokemeyer, Javier P. Gisbert, Division of Gastroenterology [University Hospitals Leuven], University Hospitals Leuven [Leuven], Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service d'Hépato-gastro-entérologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), DRK Kliniken Berlin, Westend, Instituto de Salud Carlos III [Madrid] (ISC), Hospital de la Princesa, Gastroenterology Unit [Glasgow Royal Infirmary], Glasgow Royal Infirmary, Gastroenterologische Gemeinschaftspraxis Minden, Department of Gastroenterology [Evangelismos Athens General Hospital], Evangelismos Athens General Hospital, Università cattolica del Sacro Cuore [Roma] (Unicatt), Hull and East Yorkshire Eye Hospital, IMS Health [Barcelone], and Merck & Co. Inc

Subjects
Adult, Male, medicine.medical_specialty, [SDV]Life Sciences [q-bio], Disease, Severity of Illness Index, Inflammatory bowel disease, Unmet needs, 03 medical and health sciences, 0302 clinical medicine, Quality of life, Internal medicine, medicine, Humans, Control of disease, Health related quality of life, Patient Reported Outcome Measures, Disease burden, Retrospective Studies, Hepatology, business.industry, Anti-Inflammatory Agents, Non-Steroidal, Gastroenterology, Retrospective cohort study, Middle Aged, medicine.disease, Ulcerative colitis, 3. Good health, Europe, Cross-Sectional Studies, Logistic Models, 030220 oncology & carcinogenesis, Multivariate Analysis, Quality of Life, Physical therapy, Colitis, Ulcerative, Female, 030211 gastroenterology & hepatology, Observational study, business, Cohort study
Abstract

International audience; Background: Treatment of ulcerative colitis (UC) is aimed at maintaining corticosteroid-free remission and improving quality of life (QoL). Aim: Assess patients' perception of disease burden and unmet clinical needs in moderate/severe UC patients. Methods: Adults surgery-free conventionally treated patients with Mayo score >= 6 were enrolled in an observational, cross-sectional, retrospective study in 11 European countries. Disease control was defined as Mayo score 1. No corticosteroid was used the previous two months. Unmet clinical needs were defined as: non-controlled disease, self-perception of `moderate'/'severe' disease, and dissatisfaction with treatments. Disease burden on QoL and work productivity were assessed (EuroQol-5D-5L, Short Inflammatory Bowel Disease Questionnaire (SIBDQ) and Work Productivity and Activity Impairment (WPAI) in UC questionnaire). Results: UC patients (n = 253) with mean Mayo score at enrolment of 4.9, 44.3% of patients had Mayo score >= 6. Main treatment was 5-ASA (75%). Overall, 25% met the composite endpoint for unmet clinical needs. Mean (SD) questionnaire scores were: EQ-5D-5L-VAS, 71 (19.1), EQ-5D-5L utility, 0.77 (0.19), SIBDQ, 4.8 (1.3), and WPAI, 26% (32%). Conclusions: Patients with moderate/severe UC in the last 12 months treated with conventional therapies felt that their disease was not controlled and 25% reported unmet clinical needs. QoL and work productivity were seriously impaired.

Published
2016

48. Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study

Author

Shaji Sebastian, Bern Bokemeyer, Sonia Rojas-Farreras, Alessandro Armuzzi, Daniel R. Gaya, Christopher M. Black, Andreas Sturm, Gert Van Assche, Tao Fan, Gerassimos J. Mantzaris, Javier P. Gisbert, Nuria Lara, Sumesh Kachroo, Laurent Peyrin-Biroulet, Qian Ding, Mark Lynam, Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service de Chirurgie Digestive Hépatobiliaire et Endocrine [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Division of Gastroenterology [University Hospitals Leuven], University Hospitals Leuven [Leuven], Department of Gastroenterology [DRK Kliniken Berlin], DRK Kliniken Berlin, Westend, Instituto de Salud Carlos III [Madrid] (ISC), Instituto de Investigacion Sanitaria Princesa, Gastroenterology Unit [Glasgow Royal Infirmary], Glasgow Royal Infirmary, Gastroenterologische Gemeinschaftspraxis Minden, Department of Gastroenterology [Evangelismos Athens General Hospital], Evangelismos Athens General Hospital, Complesso Integrato Columbus, Hull and East Yorkshire Eye Hospital, IMS Health [Barcelone], and Merck & Co. Inc

Subjects
Male, Pediatrics, Health Knowledge, Attitudes, Practice, [SDV]Life Sciences [q-bio], Alternative medicine, Disease, Inflammatory bowel disease, Severity of Illness Index, Trial, 0302 clinical medicine, Surveys and Questionnaires, Anti-Inflammatory Agents, Non-Steroidal, Gastroenterology, Middle Aged, Ulcerative colitis, 3. Good health, Management, Europe, Patient Satisfaction, 030220 oncology & carcinogenesis, Perspective, 030211 gastroenterology & hepatology, Female, Adult, medicine.medical_specialty, Unmet needs, 03 medical and health sciences, Patient satisfaction, Physicians, medicine, Humans, Disease burden, Retrospective Studies, Physician-Patient Relations, Hepatology, business.industry, Retrospective cohort study, medicine.disease, Cross-Sectional Studies, Logistic Models, Family medicine, Online Survey, Multivariate Analysis, Quality of Life, Observational study, Colitis, Ulcerative, business, Needs, Inflammatory-Bowel-Disease
Abstract

Background Ulcerative colitis (UC) is a life time disease and issues with therapy may impact on patient satisfaction and treatment preferences. Aims To assess disease and treatment perception gaps from patients’ and physicians’ perspectives in UC patients. Methods Adult patients with moderate-to-severe UC (Mayo score ≥6) naive to biologic therapy were enrolled in a European, observational, cross-sectional, retrospective study. Treatment satisfaction was assessed by the TSQM questionnaire and treatment preferences and patient's knowledge with pre-defined questions. Physicians’ and patients’ perceptions were compared through the level of agreement. Results 256 patients from 11 European countries were included. 48.0% of patients were dissatisfied with their current treatment. Effectiveness, long lasting action, rapid start of action, and fewer side effects were the attributes more frequently considered important or very important by patients (96.9%, 89.1%, 83.8%, and 81.8%, respectively). 26.2% patients rated their overall disease knowledge as very knowledgeable. The agreement between patients’ and physicians on disease severity was good (kappa = 0.62). Conclusion Half patients with moderate-to-severe UC managed with conventional therapy, are dissatisfied with their treatments. Effectiveness, long lasting action and rapidity of action were the most frequently rated items in treatment preferences. There are major gaps between physicians and patients when evaluating disease burden.

Published
2016

49. Identification and molecular characterization of oat peptides implicated on coeliac immune response

Author

Emmanuelle Bancel, Stella C. Knight, Gérard Branlard, David Bernardo, Borja Sánchez, Carolina Sousa, Angel Cebolla, Paul J. Ciclitira, Tanja Šuligoj, Francisco Barro, María de Lourdes Moreno, Isabel Comino, Department of Microbiology and Parasitology, Faculty of Pharmacy, Hospital Universitario Virgen del Rocío [Sevilla], Hospital Universitario La Princesa, Génétique Diversité et Ecophysiologie des Céréales (GDEC), Institut National de la Recherche Agronomique (INRA)-Université Blaise Pascal - Clermont-Ferrand 2 (UBP), Nutrition and Bromatology Group, Analytical and Food Chemistry Department, Faculty of Food Science and Technology, Universidate de Vigo, Instituto de Agricultura Sostenible (IAS), Instituto de Agricultura, Division of Diabetes and Nutritional Sciences, Gastroenterology, King‘s College London, Biomedal SL, Gastroenterology Unit, Antigen Presentation Research Group, Imperial College London, Junta de Andalucia AGR172, Contrato de Acceso al Sistema Espanol de Ciencia, Tecnologia e Innovacion para el Desarrollo del Programa Propio de I + D+i from the Universidad de Sevilla, EMBO short-term fellowship, Biotechnology and Biological Sciences Research Council (BBSRC) Institute Strategic Programme for Gut Health and Food Safety BB/J004529/1, Biotechnology and Biological Sciences Research Cou, Junta de Andalucía, Universidad de Sevilla, EMBO, Biotechnology and Biological Sciences Research Council (UK), Hospital Universitario de La Princesa, Universidade de Vigo, Instituto de Agricultura Sostenible - Institute for Sustainable Agriculture (IAS CSIC), Consejo Superior de Investigaciones Científicas [Madrid] (CSIC), Universidad de Sevilla. Departamento de Microbiología y Parasitología, and Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Institut National de la Recherche Agronomique (INRA)

Subjects
0301 basic medicine, maladie coeliaque, cereal, medicine.drug_class, système immunitaire, aliment sans gluten, lcsh:TX341-641, Monoclonal antibody, Oats, Coeliac disease, immune response, 03 medical and health sciences, 0302 clinical medicine, Immune system, céréale, gluten-free diet, Gluten-sensitive enteropathy, medicine, otorhinolaryngologic diseases, Food and Nutrition, Prolamin, Immune response, oats, gluten-sensitive enteropathy, Nutrition and Dietetics, biology, business.industry, Public Health, Environmental and Occupational Health, food and beverages, medicine.disease, 3. Good health, 030104 developmental biology, coeliac disease, Alimentation et Nutrition, Immunology, biology.protein, Gluten-free diet, 1111 Nutrition And Dietetics, 030211 gastroenterology & hepatology, Original Article, Nutrition research, Antibody, business, lcsh:Nutrition. Foods and food supply, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, 0908 Food Sciences, Food Science
Abstract

Comino, Isabel et al., [Background] Oats provide important nutritional and pharmacological properties, although their safety in coeliac patients remains controversial. Previous studies have confirmed that the reactivity of the anti-33-mer monoclonal antibody with different oat varieties is proportional to the immune responses in terms of T-cell proliferation. Although the impact of these varieties on the adaptive response has been studied, the role of the dendritic cells (DC) is still poorly understood. The aim of this study is to characterize different oat fractions and to study their effect on DC from coeliac patients., [Methods and results] Protein fractions were isolated from oat grains and analyzed by SDS–PAGE. Several proteins were characterized in the prolamin fraction using immunological and proteomic tools, and by Nano-LC-MS/MS. These proteins, analogous to α- and γ-gliadin-like, showed reactive sequences to anti-33-mer antibody suggesting their immunogenic potential. That was further confirmed as some of the newly identified oat peptides had a differential stimulatory capacity on circulating DC from coeliac patients compared with healthy controls., [Conclusions] This is the first time, to our knowledge, where newly identified oat peptides have been shown to elicit a differential stimulatory capacity on circulating DC obtained from coeliac patients, potentially identifying immunogenic properties of these oat peptides., This study was supported by a grant (Project AGR172) from the Junta de Andalucía. IC was supported by the Contrato de Acceso al Sistema Español de Ciencia, Tecnología e Innovación para el Desarrollo del Programa Propio de I + D+i from the Universidad de Sevilla and the EMBO short-term fellowship. DB and SCK were supported by the Biotechnology and Biological Sciences Research Council (BBSRC) Institute Strategic Programme for Gut Health and Food Safety BB/J004529/1.

Published
2016

50. Liver-FibroSTARD checklist and glossary: tools for standardized design and reporting of diagnostic accuracy studies of liver fibrosis tests

Author

Jérôme Guéchot, Jérôme Boursier, Victor de Ledinghen, Thierry Poynard, Fabrice Carrat, Vincent Leroy, Grace Lai-Hung Wong, Mireen Friedrich-Rust, Mirella Fraquelli, Mario Plebani, Giada Sebastiani, Robert Myers, Paul Angulo, Sandrine Bertrais, Dominique Wendum, Ivan Bricault, Paul Calès, null from the ARDENT group and/or AFEFª, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hémodynamique, Interaction Fibrose et Invasivité tumorales Hépatiques (HIFIH), Université d'Angers (UA), Centre d'investigation de la fibrose hépatique [CHU de Bordeaux] (Hôpital Haut-Lévêque ), Hôpital Haut-Lévêque [CHU de Bordeaux], Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Pierre et Marie Curie - Paris 6 (UPMC), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hépato-gastroentérologie [CHU Grenoble Alpes], Centre Hospitalier Universitaire Grenoble Alpes (CHU Grenoble Alpes), II Gastroenterology Unit, Department of Medicine, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Department of Gastroenterology, Feltre Hospital, Technische Universität Braunschweig = Technical University of Braunschweig [Braunschweig], Service de Pathologie [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Gestes Medico-chirurgicaux Assistés par Ordinateur (TIMC-IMAG-GMCAO), Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Service central de radiologie et d'imagerie médicale, CHU Grenoble-Hôpital Michallon, Centre Hospitalier Universitaire [Grenoble] (CHU), and Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Liver Cirrhosis, Research Report, medicine.medical_specialty, Glossary, [SDV]Life Sciences [q-bio], Liver fibrosis, Clinical Biochemistry, MEDLINE, Diagnostic accuracy, Humans, Liver Function Tests, Reference Standards, Reproducibility of Results, Checklist, Data Accuracy, Biochemistry (medical), Fibrosis, Data accuracy, medicine, Medical physics, Reference standards, business.industry, General Medicine, medicine.disease, 3. Good health, Radiology, business
Abstract

International audience; Chronic liver diseases are highly prevalent and require an accurate evaluation of liver fibrosis to determine patient management. Many efforts have been made over this last decade to develop accurate non-invasive tools for liver fibrosis evaluation as alternative methods to liver biopsy. These non-invasive methods of liver fibrosis assessment including blood markers and liver stiffness measurement by elastography are increasingly well validated and contribute to safer and more practical clinical care for patients [1, 2]. These efforts have led to a dramatic increase in the number of diagnostic accuracy studies of liver fibrosis tests and to a proliferation of reports whose quality is very heterogeneous. [...]

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results